



NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™)

Adult Cancer Pain

Version 1.2011

NCCN.org

Continue



National
Comprehensive
Cancer
Network®

NCCN Guidelines™ Version 1.2011 Panel Members

Adult Cancer Pain

[NCCN Guidelines Index](#)
[Adult Cancer Pain TOC](#)
[Discussion](#)

* **Robert Swarm, MD/Chair** φ £
Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University
School of Medicine

Betty Ferrell, RN, PhD £ #
City of Hope Comprehensive Cancer Center

Linda Oakes, RN, MSN #
St. Jude Children's Research Hospital/
University of Tennessee Cancer Institute

Nora A. Janjan, MD, MPSA, MBA §
The University of Texas MD Anderson Cancer
Center

Judy Paice, PhD, RN £ #
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Mihir M. Kamdar, MD ⊃ £
Massachusetts General Hospital Cancer
Center

Michael W. Rabow, MD ⊃ £
UCSF Helen Diller Family Comprehensive
Cancer Center

Sloan Beth Karver, MD £
H. Lee Moffitt Cancer Center & Research
Institute

Karen L. Syrjala, PhD θ
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance

Michael H. Levy, MD, PhD £ †
Fox Chase Cancer Center

Susan Urba, MD £ †
University of Michigan Comprehensive
Cancer Center

Maureen Lynch, RN, NP £ #
Dana-Farber/Brigham and Women's Cancer
Center

Sharon M. Weinstein, MD £ Ψ
Huntsman Cancer Institute at the
University of Utah

Natalie Moryl, MD ⊃ £
Memorial Sloan-Kettering Cancer Center

NCCN
Mary Dwyer, MS
Rashmi Kumar, PhD

Barbara A. Murphy, MD £ †
Vanderbilt-Ingram Cancer Center

Suzanne Nesbit, PharmD, BCPS Σ
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins

φ Anesthesiology
£ Supportive Care including Palliative, Pain
management, Pastoral care and Oncology social work
† Medical oncology
⊃ Internal medicine
θ Psychiatry, psychology, including health behavior
Nursing
§ Radiotherapy/Radiation oncology
Σ Pharmacology
Ψ Neurology/neuro-oncology
* Writing Committee member

Amy Pickar Abernethy, MD † £
Duke Cancer Institute

Doralina L. Anghelescu, MD φ
St. Jude Children's Research
Hospital/University of Tennessee Cancer
Institute

Costantino Benedetti, MD φ £
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Barry Boston, MD £ †
St. Jude Children's Hospital/University of
Tennessee Cancer Institute

Charles Cleeland, PhD θ
The University of Texas MD Anderson
Cancer Center

Nessa Coyle, PhD, NP £ #
Memorial Sloan-Kettering Cancer Center

Oscar A. deLeon-Casasola, MD φ £
Roswell Park Cancer Institute

June G. Eilers, RN, PhD #
UNMC Eppley Cancer Center at The
Nebraska Medical Center

Continue

[NCCN Guidelines Panel Disclosures](#)



National
Comprehensive
Cancer
Network®

NCCN Guidelines™ Version 1.2011 Table of Contents

Adult Cancer Pain

[NCCN Guidelines Index](#)
[Adult Cancer Pain TOC](#)
[Discussion](#)

[NCCN Adult Cancer Pain Panel Members](#)

[Summary of the Guidelines Updates](#)

[Universal Screening and Assessment \(PAIN-1\)](#)

[Management of Pain in Opioid Naïve Patients \(PAIN-2\)](#)

[Initiating Short-acting Opioids in Opioid Naïve Patients \(PAIN-3\)](#)

[Management of Pain in Opioid Tolerant Patients \(PAIN-4\)](#)

[Subsequent Pain Management and Treatment in Opioid Tolerant Patients \(PAIN-5\)](#)

[Ongoing Care \(PAIN-6\)](#)

[Pain Intensity Rating \(PAIN-A\)](#)

[Procedure-Related Pain and Anxiety \(PAIN-B\)](#)

[Comprehensive Pain Assessment \(PAIN-C\)](#)

[Additional Interventions for Cancer Pain Syndromes \(PAIN-D\)](#)

[Opioid Principles, Prescribing, Titration, and Maintenance \(PAIN-E\)](#)

[Management of Opioid Adverse Effects \(PAIN-F\)](#)

[Adjuvant Analgesics for Neuropathic Pain \(PAIN-G\)](#)

[Psychosocial Support \(PAIN-H\)](#)

[Patient and Family Education \(PAIN-I\)](#)

[Nonpharmacologic Interventions \(PAIN-J\)](#)

[Non-Opioid Analgesic \(Nonsteroidal Anti-inflammatory Drugs \[NSAID\] and Acetaminophen\)](#)

[Prescribing \(PAIN-K\)](#)

[Specialty Consultations for Improved Pain Management \(PAIN-L\)](#)

[Interventional Strategies \(PAIN-M\)](#)

Clinical Trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN member institutions, [click here: nccn.org/clinical_trials/physician.html](#)

NCCN Categories of Evidence and Consensus: All recommendations are Category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#)

The NCCN Guidelines™ are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2011.

**Updates in Version 1.2011 of the NCCN Adult Cancer Pain Guidelines from Version 1.2010 include:****PAIN-1**

- Universal screening, if pain present, first bullet was modified by adding a link, “See Comprehensive Pain Assessment (See PAIN-C)”.

PAIN-3

- Initiating short-acting opioids in opioid naïve patients
 - For IV bolus, the qualifier “administered by healthcare provider” was removed. Also for PAIN-4.
 - Footnote ‘c’, was modified, from “... subcutaneous route delays onset of effect by up to 30 minutes” to “...peak effect subcutaneously is usually 30 min.” Also for PAIN-4.

PAIN-5

- The title was modified from “subsequent pain management and treatment in opioid tolerant patients” to “subsequent pain management”.
- The following bullets were added to “ALL levels of pain”:
 - For persistent pain, initiate regular schedule of opioid with rescue dose as needed
 - Continue management of constipation (See PAIN-F)

PAIN-6

- First bullet, a new subbullet, “Simplify analgesic regimen for improved patient compliance, if feasible” was added.
- Fourth bullet, “Collaborate with patient’s pharmacist” was added.
- Sixth bullet, three new subbullets were added:
 - Pharmacy benefit coverage
 - Availability of analgesics
 - Local laws/regulations
- Seventh bullet, the second subbullet was modified from “maintain clinic appointments” to “schedule and keep outpatient appointments”.
- The ninth bullet, “Maintain communication and coordinate care with pain specialist and relevant providers” was modified by adding “especially during transition between sites of care”.

PAIN-A 1 of 2

- First bullet regarding the use of the pain intensity ratings scale was modified as, “At minimum, patients should be asked about “current” pain, as well as “worst” pain, “usual” pain, and “least” pain” in the past 24 hours. *For each pain intensity rating, use one of the scales below.*”
- Categorical scale question was changed from “What is the level of your pain?” to “What word best describes your pain?”.

PAIN-A 2 of 2

- The last bullet regarding the importance of cultural and linguistic assessment was modified by adding, “and respond with trained interpreters and culturally and linguistically appropriate educational materials”.

PAIN-B

- The following bullets were added:
 - Analgesics
 - ◊ Supplemental doses of analgesics should be given in anticipation of procedure-related pain.
 - ◊ If procedure or transportation precludes continuation of IV PCA, give the prescribed IV bolus dose immediately before procedure/transport and administer a subcutaneous dose equivalent to 2 h basal infusion rate.
 - Anxiolytics should be given preemptively when feasible.

PAIN-C 1 of 2

- Special issues relating to pain, the following bullet was added:
 - Assess for use of alternative, complementary, or herbal therapies and screen for potential adverse interactions or effects.

PAIN-D

- Neuropathic pain, for both a trial of antidepressant and anticonvulsant, the dose management was clarified from “start with low dose and increase every 3-5 days if tolerated or lengthen interval up to 14 days” to “start with low dose and increase every 3-14 days as tolerated”.



Updates in Version 1.2011 of the NCCN Adult Cancer Pain Guidelines from Version 1.2010 include:

[PAIN-E 1 of 7](#)

- General principles:
 - A new principle, “Titrate with caution in patients with risk factors such as decreased renal/hepatic function, sleep apnea, poor performance status” was added.
- Principles of opioid maintenance:
 - Third bullet, a new subbullet, “Initial range for converting to long-acting opioid would be 50% of the daily requirement” was added.

[PAIN-E 2 of 7](#)

- Parental dose for codeine was removed from the table.
- Propoxyphene was removed from the ‘not recommended’ list as it is no longer FDA approved.
- Footnote 1, was modified as “Codeine, morphine, or *hydromorphone* should be used with caution in patients with *fluctuating* renal function due to *potential* accumulation of renally-cleared metabolites - *monitor for neurologic adverse effects.*”

[PAIN-E 6 of 7](#)

- First bullet, “Due to the unique nature of methadone with a long and variable half life, caution should be used and frequent and careful evaluation should be performed” was added to the page.
- Second bullet was modified by adding, “Practitioners are advised to consult with a pain or palliative care specialist if they are unfamiliar with methadone prescribing.”
- Sixth bullet, “Methadone is typically given at a regular schedule with additional doses of a short-acting opioid given as needed” was added to the page.
- Seventh bullet was modified by adding, “QTc \geq 450 may indicate need to reduce or discontinue methadone dose.”

[PAIN-F 1 of 3](#)

- Three new principles of management of opioid adverse effects were added:
 - Patient/family education is essential for successful management of pain and opioid adverse effects.
 - Recognize adverse effects to opioids are common, should be anticipated, and managed aggressively.
 - Information from patient/family about adverse effects is essential for appropriate opioid dose adjustment and treatment of adverse effects.
- Constipation, prophylactic medications, “polyethylene glycol (1 capful/8 oz water PO two times a day)” was added.

[PAIN-G 2 of 2](#)

- Title was changed from “co-analgesics for neuropathic pain” to “adjuvant analgesics for neuropathic pain”.
- The following was added to the page, “Note: Some antidepressants, (especially duloxetine, bupropion) may enhance metabolism of tamoxifen and thereby limit tamoxifen efficacy - see discussion (MS-10).”

[PAIN-H](#)

- Skills training, first bullet was modified by adding, “to be used in conjunction with and not in lieu of appropriate analgesia”.

[PAIN-I](#)

- First bullet “Healthcare team should:” a new subbullet was added, “Assess patient and family existing knowledge of pain and pain treatment to aid in developing appropriate patient/family education plan” with corresponding references.
- Third bullet, seventh subbullet, “Patients with pain often have other symptoms (eg, constipation, nausea, fatigue, insomnia, depression) that need to be controlled, management of these other symptoms may facilitate control of pain” was added to the page.
- Third bullet, eleventh subbullet, was modified by adding, “Communication with the healthcare provider is critical for them to assist in meeting goals of care.” In addition, “Describing your pain is not viewed as ‘complaining’ but as an essential source of information for your health care provider to adjust your treatment” was added to the first tertiary bullet.

[PAIN-J](#)

- “Consider nonpharmacologic interventions” was modified by adding, “in conjunction with pharmacologic interventions as needed.”

[PAIN-K](#)

- Title of the page was revised by adding, “non-opioid analgesic”.
- NSAID toxicities, patients at high risk for renal toxicities, “multiple myeloma and diabetes” were added.

[PAIN-L](#)


- Spiritual care, a new bullet, “management of spiritual, existential concerns” was added.
- Physical/occupational therapy, rehabilitation/mobility specialists:
 - “Lymphedema management” was added.
 - Physical modalities, “energy conservation, pacing of activities” was added.



UNIVERSAL SCREENING

ASSESSMENT

MANAGEMENT OF PAIN



^aOpioid naïve includes patients who are not chronically receiving opioid analgesic on a daily basis.

^bOpioid tolerant includes patients who are chronically receiving opioid analgesic on a daily basis.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PAIN INTENSITY

[See Pain Intensity Rating \(PAIN-A\)](#)

For ALL levels of pain →

MANAGEMENT OF PAIN IN OPIOID NAÏVE PATIENTS^a

- Recognize and treat analgesic adverse effects ([See PAIN-F](#))
- Consider adding co-analgesics ([See PAIN-G](#)) for specific pain syndrome ([See PAIN-D](#))
- Provide psychosocial support ([See PAIN-H](#))
- Provide patient and family education ([See PAIN-I](#))
- Optimize nonpharmacologic interventions ([See PAIN-J](#))

Severe Pain 7-10 →

- See management for *all* levels of pain above AND
- Rapidly titrate short-acting opioid, [see PAIN-3](#) for initiating short-acting opioids and [see PAIN-E](#) for additional details of opioid principles, prescribing, titration, and maintenance
 - ▶ Begin bowel regimen ([See PAIN-F](#))

Moderate Pain 4-6 →

- See management for *all* levels of pain above AND
- Titrate short-acting opioid, [see PAIN-3](#) for initiating short-acting opioids and [see PAIN-E](#) for additional details of opioid principles, prescribing, titration, and maintenance
 - ▶ Begin bowel regimen ([See PAIN-F](#))

Mild Pain 1-3 →

- See management for *all* levels of pain above AND
- Consider nonsteroidal anti-inflammatory drugs (NSAID) or acetaminophen without opioid if patient is not on analgesics ([See PAIN-K](#)) or
- Consider titrating short-acting opioid ([See PAIN-E](#))
 - ▶ Begin bowel regimen ([See PAIN-F](#))

Reevaluate pain at each contact and as needed to meet patient goals for comfort and function

[See Ongoing Care \(PAIN-6\)](#)

^aOpioid naïve includes patients who are not chronically receiving opioid analgesic on a daily basis.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



INITIATING SHORT-ACTING OPIOIDS IN OPIOID NAÏVE PATIENTS^a

Monitor for acute and chronic adverse effects. ([See Management of Opioid Adverse Effects PAIN-F](#))

Opioid naïve patients^a



^aOpioid naïve includes patients who are not chronically receiving opioid analgesic on a daily basis.

^cSubcutaneous can be substituted for intravenous, however peak effect subcutaneously is usually 30 min.


Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



MANAGEMENT OF PAIN IN OPIOID TOLERANT PATIENTS^b

Monitor for acute and chronic adverse effects. ([See Management of Opioid Adverse Effects PAIN-F](#))

Opioid tolerant patients^b



^bOpioid tolerant includes patients who are chronically receiving opioid analgesic on a daily basis.

^cSubcutaneous can be substituted for intravenous, however peak effect subcutaneously is usually 30 min.


Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PAIN INTENSITY
[See Pain Intensity Rating \(PAIN-A\)](#)

SUBSEQUENT PAIN MANAGEMENT^b

GOALS OF TREATMENT



^bOpioid tolerant includes patients who are chronically receiving opioid analgesic on a daily basis.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




ONGOING CARE

Clinician responsibilities

- **Convert to oral medications (if feasible) including extended-release agent with rescue doses (Conversion details, [see PAIN-E](#))**
 - **Simplify analgesic regimen for improved patient compliance, if feasible.**
- **Routine follow-up**
 - **Assess pain during each outpatient contact or at least each day for inpatients or more frequently based on:**
 - ◆ Patient's condition
 - ◆ Institutional standards
 - ◆ Regulatory requirements
- **Provide written follow-up pain plan, including prescribed medications ([See PAIN-I](#))**
- **Collaborate with patient's pharmacist**
- **Ensure adequate access to prescribed medications, especially during transition between sites of care**
- **Address system barriers**
 - Pharmacy benefit coverage
 - Availability of analgesics
 - Local laws/regulations
 - Obtain assistance from social services
- **Instruct the patient on the importance of the following:**
 - Follow documented pain plan ([See PAIN-I](#))
 - Schedule and keep outpatient appointments
 - Contact clinician if pain worsens or adverse effects inadequately controlled
- **Process realistic goals, revise, and review**
- **Maintain communication and coordinate care with pain specialist and relevant providers, especially during transition between sites of care**
- **On-call/as needed availability**

GOALS OF TREATMENT



Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PAIN INTENSITY RATING (1 of 2)

- Pain intensity rating scales can be used as part of universal screening and comprehensive pain assessment. At minimum, patients should be asked about “current” pain, as well as “worst” pain, “usual” pain, and “least” pain in the past 24 hours. For each pain intensity rating, use one of the scales below.
- For comprehensive assessment, also include “worst pain in past week,” “pain at rest,” and “pain with movement”. [See Comprehensive Pain Assessment \(PAIN-C\)](#) for more details.

Table 1: Numerical Rating Scale

Numerical rating scale:

- Verbal: “What number describes your pain from 0 (no pain) to 10 (worst pain you can imagine)?”
- Written: “Circle the number that describes your pain.”




Categorical scale:

“What word best describes your pain?”

None (0), Mild (1–3), Moderate (4–6), or Severe (7–10)

Table 2: The Faces Pain Rating Scale - Revised^{1,2}



Instructions: “These faces show how much something can hurt. This face (point to the left-most face) shows no pain. Each face shows more and more pain (point to each face from left to right) up to this one (point to the right-most face)- it shows very much pain. Point to the face that shows how much you hurt (right now).”

¹Hicks CL, von Baeyer CL, Spafford P, et al. The Faces Pain Scale - Revised: Toward a common metric in pediatric pain measurement. *Pain* 2001;93:173-183.

²Ware LJ, Epps CD, Herr K, Packard A. Evaluation of the Revised Faces Pain Scale, Verbal Descriptor Scale, Numeric Rating Scale, and Iowa Pain Thermometer in older minority adults. *Pain Manag Nurs* 2006;7:117-125.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued on next page](#)
[PAIN-A 2 of 2](#)



PAIN INTENSITY RATING (2 of 2)

Pain assessment in the nonverbal patient¹

- **The inability of patients to verbally communicate pain intensity because of cognitive or physiologic issues is a major barrier relating to pain assessment and management. Therefore, the American Society for Pain Management Nursing (www.aspmn.org) has developed a position statement and clinical practice recommendations clinicians may find useful in caring for such patients.**
- **In the absence of self-report, observation of behavior is a valid approach to pain assessment with the understanding that behaviors may also indicate another source of distress such as emotional distress. Potential causes and the context of the behavior must be considered when making pain treatment decisions.**
- **A multi-faceted approach is recommended that combines direct observation, family/caregiver input, and evaluation of response to pain medicines or nonpharmacologic interventions.**
- **For patients with advanced dementia, a comprehensive review of currently published tools is available at http://prc.coh.org/pain_assessment.asp. These tools are in varying stages of development and validation and include but are not limited to:**
 - ▶ **The Assessment of Discomfort in Dementia Protocol (ADD)**²
 - ▶ **Checklist of Nonverbal Pain Indicators (CNPI)**³
 - ▶ **The Pain Assessment in Advanced Dementia Scale (PAINAD)**⁴
- **For patients who are intubated and/or are unconscious, pain assessment tools have been tested in specific situations and include but are not limited to:**
 - ▶ **Behavioral Pain Scale (BPS)**;⁵ tested in adults and intensive care
 - ▶ **Critical-Care Pain Observation Tool (CPOT)**;⁶ tested in adults and intensive care
- **Clinicians are encouraged to monitor current research regarding new developments in strategies and tools for assessing pain in patients who have difficulty with self-report.**

Cultural and linguistic assessment^{7,8}

- **Healthcare providers should be aware of impact of cultural and linguistic diversity during universal screening and comprehensive pain assessment and respond with trained interpreters and culturally and linguistically appropriate educational materials.**

¹Herr K, Coyne P, Key T, et al. Pain assessment in the nonverbal patient: Position statement with clinical practice recommendations. *Pain Manag Nurs* 2006;7:44-52.

²Kovach CR, Noonan PE, Griffie J, Muchka S, Weissman DE. The assessment of discomfort in dementia protocol. *Pain Manag Nurs*. 2002;3:16-27.

³Feldt KS. Checklist of nonverbal pain indicators. *Pain Management Nursing* 2000;1:13-21.

⁴Lane P, Kuntupis M, MacDonald S, et al. A pain assessment tool for people with advanced Alzheimer's and other progressive dementias. *Home Healthc Nurse* 2003;21:32-37.

⁵Payen JF, Bru O, Bosson JL, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. *Crit Care Med* 2001;29:2258-2263.

⁶Gélinas C, Johnston C, et al. Pain assessment in the critically ill ventilated adult: validation of the Critical-Care Pain Observation Tool and physiologic indicators. *Clin J Pain* 2007;23:497-505.

⁷Al-Atiyyat HNM. Cultural diversity and cancer pain. *Journal of Hospice & Palliative Nursing* 2009;11:154-164

⁸Ezenwa MO, Ameringer S, Ward SE, Serlin RC. Racial and ethnic disparities in pain management in the United States. *J Nurs Scholarsh* 2006;38:225-233.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PROCEDURE-RELATED PAIN AND ANXIETY

- **Consistent adequate analgesia for all pain-related procedures and anxiety is critical.**
- **Providing information regarding all of the analgesic techniques described below prior to the procedure is ideal as it allows the patient and their family the time they may need to assimilate all of the information, ask questions, and master the techniques while reducing anticipatory anxiety.**
- **Events that are expected to cause discomfort to the patient such as diagnostic and therapeutic procedures (eg, wound care, IV, arterial line, central line, injection, manipulation, bone marrow aspiration, lumbar puncture, skin biopsy, bone marrow biopsy) as well as transportation/change in position for patient's with incident pain, should merit pre-treatment with an analgesic intervention.**
- **Intervention may be multi-modal and potentially include one or more of the following as appropriate.**
 - ▶ **Analgesics**
 - ◊ **Additional analgesics and/or local anesthetics should be available immediately for further titration as needed.**
 - ◊ **Supplemental doses of analgesics should be given in anticipation of procedure-related pain.**
 - ◊ **If procedure or transportation precludes continuation of IV patient-controlled analgesia (PCA), give the prescribed IV bolus dose immediately before procedure/transport and administer a subcutaneous dose equivalent to 2 h basal infusion rate.**
 - ▶ **Anxiolytics should be given preemptively when feasible.**
 - ▶ **Local anesthetics such as:**
 - ◊ **Topical local anesthetics creams (containing lidocaine, prilocaine, tetracaine) applied to intact skin with sufficient time for effectiveness as per package insert.**
 - ◊ **Physical approaches (ultrasound, cutaneous warming, laser or jet injection) may accelerate the onset of cutaneous anesthesia.**
 - ◊ **Ionophoretic devices to provide lidocaine delivery through the skin without needles in 10-15 min.**
 - ◊ **Subcutaneous administration of lidocaine with a 27 gauge needle.**
 - ▶ **Administration of sedatives/analgesics/general anesthesia by trained personnel.**
 - ▶ **Nonpharmacologic interventions for relief of pain and/or anxiety ([See PAIN-J](#))**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**COMPREHENSIVE PAIN ASSESSMENT**

Patient's self report of pain is the standard of care. If the patient is unable to verbally report pain, an alternative method to obtain pain rating and response should be utilized ([See PAIN-A 2 of 2](#)).

- Pain Experience

- ▶ Location, referral pattern, radiation of pain(s)
- ▶ Intensity [See Pain Intensity Rating \(PAIN-A\)](#)
 - ◊ Last 24 hours and current pain
 - ◊ At rest and with movement
- ▶ Interference with activities
[See Impact of Pain Measurement \(PAIN-C 2 of 2\)](#)
 - ◊ General activity, mood, relationship with others, sleep, appetite
- ▶ Timing: onset, duration, course, persistent, or intermittent
- ▶ Description or quality
 - ◊ Aching, stabbing, throbbing, pressure often associated with somatic pain in skin, muscle, bone
 - ◊ Gnawing, cramping, aching, sharp often associated with visceral pain in organs or viscera
 - ◊ Sharp, tingling, ringing, shooting often associated with neuropathic pain caused by nerve damage
- ▶ Aggravating and alleviating factors
- ▶ Other current symptoms
- ▶ Current pain management plan, both pharmacologic and non-pharmacologic. If medications are used, determine
 - ◊ What medication(s), prescription and/or over the counter?
 - ◊ How much?
 - ◊ How often?
 - ◊ Current prescriber?
- ▶ Response to current therapy
 - ◊ Pain relief
 - ◊ Patient adherence to medication plan
 - ◊ Medication adverse effects such as constipation, sedation, cognitive slowing, nausea, others
- ▶ Prior pain therapies
 - ◊ Reason for use, length of use, response, reasons for discontinuing, adverse effects encountered

- ▶ Special issues relating to pain
 - ◊ Meaning and consequences of pain for patient and family
 - ◊ Patient and family knowledge and beliefs surrounding pain and pain medications
 - ◊ Cultural beliefs toward pain and pain expression
 - ◊ Spiritual, religious considerations, and existential suffering
 - ◊ Patient goals and expectations regarding pain management
 - ◊ Assess for use of alternative, complementary, or herbal therapies and screen for potential adverse interactions or effects
- Psychosocial ([See PAIN-H](#))
 - ▶ Patient distress [See NCCN Distress Management Guidelines](#)
 - ▶ Family and other support
 - ▶ Psychiatric history including current or prior patient, family, or household history of substance abuse
 - ▶ Risk factors for aberrant use or diversion of pain medication
 - ◊ Patient, environmental, and social factors
 - ▶ Risk factors for undertreatment of pain
 - ◊ Pediatric, geriatric, minorities, female, communication barriers, history of substance abuse, neuropathic pain, and cultural factors
- Medical history
 - ▶ Oncologic treatment including current and prior chemotherapy, radiation therapy, and surgery
 - ▶ Other significant illnesses, conditions
 - ▶ Pre-existing chronic pain
- Physical examination
- Relevant laboratory and imaging studies to evaluate for disease progression
- The endpoint of the assessment is to establish the “pain diagnosis” and individualized pain treatment plan based on mutually developed goals. The “pain diagnosis” includes the etiology and pathophysiology of pain:
 - ▶ Etiology
 - ◊ Cancer
 - ◊ Cancer therapy (RT, chemotherapy, surgery) or procedures
 - ◊ Coincidental or noncancer
 - ▶ Pathophysiology
 - ◊ Nociceptive ◊ Neuropathic

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Return to Initial Screening \(PAIN-1\)](#)



NCCN Guidelines™ Version 1.2011

Adult Cancer Pain

IMPACT OF PAIN MEASUREMENT^{1,2,3}

Mark the number that describes how much, in the past [week / 24 hours] pain has interfered with your:

1. General Activity 0 1 2 3 4 5 6 7 8 9 10 Does not Interfere Completely Interferes
2. Mood 0 1 2 3 4 5 6 7 8 9 10 Does not Interfere Completely Interferes
3. Walking Ability 0 1 2 3 4 5 6 7 8 9 10 Does not Interfere Completely Interferes
4. Normal Work (includes both work outside the home and housework) 0 1 2 3 4 5 6 7 8 9 10 Does not Interfere Completely Interferes
5. Relations with other people 0 1 2 3 4 5 6 7 8 9 10 Does not Interfere Completely Interferes
6. Sleep 0 1 2 3 4 5 6 7 8 9 10 Does not Interfere Completely Interferes
7. Enjoyment of life 0 1 2 3 4 5 6 7 8 9 10 Does not Interfere Completely Interferes

¹ Cleeland CS, Nakamura Y, Mendoza et al. Dimensions of the impact of cancer pain in a four country sample: New information from multidimensional scaling. Pain 1996;67:267-273.

² Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-284.

³ For the complete Brief Pain Inventory assessment tool, see mdanderson.org/bpi

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



ADDITIONAL INTERVENTIONS FOR CANCER PAIN SYNDROMES

In general, cancer pain is treated with opioids as indicated on [PAIN-2](#), these interventions are meant to complement management.

- Pain associated with inflammation:
 - ▶ Trial of NSAIDs or glucocorticoids
- Nerve compression or inflammation:
 - ▶ Trial of glucocorticoids
- Bone pain without oncologic emergency:
 - ▶ NSAIDs and titrate analgesic to effect
[See Nonsteroidal Anti-inflammatory Drugs \(NSAID\) and Acetaminophen Prescribing \(PAIN-K\)](#)
 - ▶ Local bone pain: consider local radiation therapy or nerve block (eg, rib pain)
 - ▶ Diffuse bone pain: consider trial of bisphosphonates, hormonal or chemotherapy, glucocorticoids and/or systemic administration of radioisotopes
 - ▶ Consider physical medicine evaluation
[See Pain Specialty Consultation \(PAIN-L\)](#)
 - ▶ For resistant pain: consider referral to a pain specialist and/or the use of interventional strategies.
[See Interventional Strategies \(PAIN-M\)](#)
- Bowel obstruction
 - ▶ Bowel rest, nasogastric suction, glucocorticoids, octreotide
- Neuropathic pain:
 - ▶ Trial of antidepressant: start with low dose and increase every 3-14 days as tolerated
(eg, nortriptyline, 10-150 mg/d; desipramine, 10-150 mg/d; venlafaxine, 37.5-225 mg/d divided in 2-3 doses; duloxetine, 30-60 mg/d
and/or
 - ▶ Trial of anticonvulsant: start with low dose and increase every 3-14 days as tolerated (eg, gabapentin, 100-1,200 mg three times a day; carbamazepine, 100-400 mg two times a day; pregabalin 100-600 mg/d divided in 2-3 doses, or other anticonvulsants
and/or
 - ▶ Consider topical agents such as local anesthetics including lidocaine patch
 - ▶ For resistant pain, consider referral to a pain specialist and/or the use of interventional strategies.
[See Interventional Strategies \(PAIN-M\)](#)
- Painful lesions that are likely to respond to antineoplastic therapies:
 - ▶ Consider trial of radiation, hormones, or chemotherapy
- For severe refractory pain in the imminently dying,
[see NCCN Palliative Care Guideline.](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



OPIOID PRINCIPLES, PRESCRIBING, TITRATION, AND MAINTENANCE (1 of 7)

GENERAL PRINCIPLES

- The appropriate dose is the dose that relieves the patient's pain throughout the dosing interval without causing unmanageable adverse effects.
- Titrate with caution in patients with risk factors such as decreased renal/hepatic function, sleep apnea, poor performance status.
- Generally, oral route is most common; however, other routes (IV, subcutaneous, rectal, transdermal, transmucosal, buccal) can be considered as indicated to maximize patient comfort. For intrathecal route administration, [see PAIN-M](#).
- Calculate dosage increase based upon total opioid dose (around the clock/scheduled and as needed) taken in the previous 24 h.
- Increase both around the clock and as needed doses. The rapidity of dose escalation should be related to the severity of the symptoms. [See Management of Pain in Opioid Tolerant Patients \(PAIN-4\)](#).
- According to FDA guidelines, switch from preparations of opioid combined with other medications (such as aspirin or acetaminophen) to pure opioid preparation if opioid dose required would result in excessive (or inadequate) dosing of the non-opioid component of combination. ([See PAIN-K](#))
- Steady state is achieved in about 5 half lives.
- If patient is experiencing unmanageable adverse effects and pain is < 4, consider downward dose titration by approximately 25% and reevaluate. Patient would require close follow-up to make sure pain did not escalate.
- Consider opioid rotation if pain inadequately controlled or persistent adverse effects from current therapy.

PRINCIPLES OF MAINTENANCE OPIOID THERAPY

- For continuous pain, it is appropriate to give pain medication on a regular schedule with supplemental doses for breakthrough pain.
- Add extended release or long-acting formulation to provide background analgesia for control of chronic persistent pain controlled on stable doses of short-acting opioids.
- Provide rescue doses of short-acting opioids for pain not relieved by extended release opioids including breakthrough pain or acute exacerbations of pain, activity or position related pain, or pain at the end of dosing interval:
 - ▶ When possible, use the same opioid for short-acting and extended release forms.
 - ▶ Allow rescue doses of short-acting opioids of 10% to 20% of 24-h oral dose (mg) every 1 h as needed. Ongoing need for repeated rescue doses may indicate a need for adjustment of regularly-scheduled opioid dose.
 - ▶ Initial range for converting to long-acting opioid would be 50% of the daily requirement.
 - ▶ Consider transmucosal fentanyl (lozenge, tablets, film) only in opioid tolerant patients for brief episodes of acute exacerbation of pain not attributed to inadequate dosing of around the clock opioid. Data do not support a specific transmucosal fentanyl dose equianalgesic to other opioids. Initiate transmucosal fentanyl with lowest dose (200 mcg lozenge or 100 mcg buccal tablet or 200 mcg buccal soluble film) and titrate to effect. (See specific transmucosal prescribing information for appropriate dosing intervals.)
- Increase dose of extended release opioid if patient persistently needs doses of as needed opioids or when dose of around the clock opioid fails to relieve pain at peak effect or at end of dose.

[Continued on next page](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



OPIOID PRINCIPLES, PRESCRIBING, TITRATION, AND MAINTENANCE (2 of 7)

Table 1 Oral and Parenteral Opioid Equivalences and Relative Potency of Drugs as Compared with Morphine Based on Single Dose Studies

<u>Opioid Agonists</u>	<u>Parenteral Dose</u>	<u>Oral Dose</u>	<u>Factor (IV to PO)</u>	<u>Duration of Action⁹</u>
Morphine ^{1,2}	10 mg	30 mg	3	3-4 h
Hydromorphone ¹	1.5 mg	7.5 mg	5	2-3 h
Fentanyl ³	100 mcg	--	--	1-3 h
Levorphanol ⁴	2 mg	4 mg	2	3-6 h
Methadone ^{4,5}	--	--	--	--
Oxycodone ⁶	--	15-20 mg	--	3-5 h
Hydrocodone ⁷	--	30-45 mg	--	3-5 h
Oxymorphone	1 mg	10 mg	10	3-6 h
Codeine ^{1,6}	--	200 mg	--	3-4 h
Tramadol ⁸	--	50-100 mg	--	3-7 h

NOT RECOMMENDED

Meperidine¹⁰

Mixed agonist-antagonists (pentazocine, nalbuphine, butorphanol, dezocine)

Special Note: Mixed agonists-antagonists have limited usefulness in cancer pain. They should NOT be used in combination with opioid agonist drugs. Converting from an agonist to an agonist-antagonist could precipitate a withdrawal crisis in the opioid dependent patient.

¹ Codeine, morphine, or hydromorphone should be used with caution in patients with fluctuating renal function due to potential accumulation of renally-cleared metabolites - monitor for neurologic adverse effects.

² Conversion factor listed for chronic dosing.

³ The equianalgesic dose listed only applies to IV fentanyl compared to other IV opioids. For transdermal fentanyl conversions, see [PAIN-E 4 of 7](#).

⁴ Long half-life, observe for drug accumulation and adverse effects after 2-5 days. May need to be dosed every 4 h initially then changed to every 6-8 h after steady state achieved (1-2 wks).

⁵ The oral conversion ratio of methadone varies. PRACTITIONERS ARE ADVISED TO CONSULT WITH A PAIN OR PALLIATIVE CARE SPECIALIST IF THEY ARE UNFAMILIAR WITH METHADONE PRESCRIBING. ([See Converting from Oral Morphine to Oral Methadone PAIN-E 7 of 7](#)).

⁶ Dosage must be monitored for safe limits as it may be available in combination with acetylsalicylic acid (ASA) or acetaminophen. Dose listed refers only to opioid portion.

⁷ Equivalence data not substantiated. Clinical experience suggests use as a mild, initial use opioid but effective dose may vary. Usually combined with ASA or acetaminophen in doses from 325 to 750 mg. Dosage must be monitored for safe limits of ASA or acetaminophen. Dose listed refers only to opioid portion.

⁸ Weak opioid receptor agonist with some antidepressant activity. For mild to moderate pain. Recommend a maximum dose of 50-100 mg four times a day (maximum daily dose 400 mg) to avoid CNS toxicity. Even at maximum dose 100 mg four times a day, tramadol is less potent than other opioid analgesics such as morphine.

⁹ Shorter time generally refers to parenterally administered opioids (except for controlled-release products which have some variability); longer time generally applies to oral dosing.

¹⁰ Not recommended for cancer pain management because of CNS toxic metabolite - normeperidine.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued on next page](#)



OPIOID PRINCIPLES, PRESCRIBING, TITRATION, AND MAINTENANCE (3 of 7)

CONVERT OR ROTATE FROM ONE OPIOID TO ANOTHER OPIOID

• **To convert or rotate from one opioid to another opioid:**

1. Determine the amount of current opioid(s) taken in a 24-h period that effectively controls pain.
2. Calculate the equianalgesic dose of the new opioid. [See Table 1 \(PAIN-E 2 of 7\)](#).
3. If pain was effectively controlled, reduce the dose by 25-50% to allow for incomplete cross-tolerance between different opioids.
During the first 24-h, titrate liberally and rapidly to analgesic effect.
4. If previous dose was ineffective, may begin with 100% or 125% of equianalgesic dose.
5. Lastly, for oral opioids divide the total daily dose of new opioid needed by the number of doses per day to determine the individual dose (eg, 6 doses for regular PO morphine every 4 hrs; 2 doses for extended release morphine every 12-h).

Case example of converting IV morphine to IV hydromorphone

A patient is taking IV morphine at 8 mg/h and needs to be converted to IV hydromorphone.

1. Determine the total amount of current IV morphine in a 24-h period for this patient
(8 mg/h x 24 hr = 192 mg/day)
(Total amount of IV morphine this patient is taking is 192 mg/day.)
2. From Table 1 on [PAIN-E 2 of 7](#), calculate the equianalgesic dose of IV hydromorphone
(10 mg IV morphine = 1.5 mg IV hydromorphone therefore,
192 mg/day IV morphine = 28.8 mg/day IV hydromorphone = 1.2 mg/h IV hydromorphone)
3. If patient was effectively controlled with IV morphine (192 mg/day) reduce the dose of hydromorphone by 25-50%.
(28.8 mg/day reduced by 25% = 21.6 mg/day IV hydromorphone = 0.9 mg/h IV hydromorphone)
(28.8 mg/day reduced by 50% = 14.4 mg/day IV hydromorphone = 0.6 mg/h IV hydromorphone)
If dose of IV morphine was ineffective in controlling pain, may begin with 100% of equianalgesic hydromorphone dose
(28.8 mg/day IV hydromorphone = 1.2 mg/h IV hydromorphone)
or increase that by 25%
(36 mg/day IV hydromorphone = 1.5 mg/h IV hydromorphone)

[Continued on next page](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



OPIOID PRINCIPLES, PRESCRIBING, TITRATION, AND MAINTENANCE (4 of 7)

CONVERT OR ROTATE FROM ANOTHER OPIOID TO TRANSDERMAL FENTANYL

• To convert or rotate from another opioid to transdermal fentanyl:

1. Determine the 24-h analgesic requirement of current opioid. Table 2 can be used directly for patients on oxycodone, hydromorphone, and codeine. If not one of these opioids, convert to equianalgesic dose of morphine requirement.
2. From Table 2, select the mcg per hour dose of transdermal fentanyl based on the 24-h dose of morphine, oxycodone, hydromorphone, or codeine as listed. For fentanyl dosage requirements > 100 mcg/h, multiple patches are used.

Note: An as needed (prn) dose of morphine or other short-acting opioid should be prescribed and will be needed particularly during the first 8 to 24-h. Once the levels have reached steady state after at least 2 - 3 days, increase the patch dosage based on the average amount of stable daily as need (prn) opioid required. Continue breakthrough medication once the patch dose is stabilized.

Table 2 Recommended Dose Conversion From Other Opioids to Transdermal Fentanyl¹

[See next page for case examples](#)

Transdermal Fentanyl	Morphine ²		Hydromorphone		Oxycodone	Codeine
	IV/SubQ *	Oral	IV/SubQ *	Oral	Oral	Oral
25 mcg/h	20 mg/d	60 mg/d	1.5 mg/d	7.5 mg/d	30 mg/d	200 mg/d
50 mcg/h	40 mg/d	120 mg/d	3.0 mg/d	15.0 mg/d	60 mg/d	400 mg/d
75 mcg/h	60 mg/d	180 mg/d	4.5 mg/d	22.5 mg/d	90 mg/d	600 mg/d
100 mcg/h	80 mg/d	240 mg/d	6.0 mg/d	30.0 mg/d	120 mg/d	800 mg/d

* Parenteral dosing such as IV (intravenous) or SubQ (subcutaneous) NOTE: Due to patient variability the doses suggested in this guide are approximate and clinical judgement must be used to titrate to the desired response.

Special Notes Regarding Transdermal Fentanyl:

- Pain should be relatively well-controlled on a short-acting opioid prior to initiating the fentanyl patch. Patches are NOT recommended for unstable pain requiring frequent dose changes. Use fentanyl patch only in patients tolerant to opioid therapy.
- Fever or topical application of heat (such as heat from heat lamps, electric blankets, etc.) may accelerate transdermal fentanyl absorption and are contraindications for transdermal fentanyl.
- When converting from continuous parenteral infusion fentanyl to transdermal fentanyl, a straight 1:1 ratio³ is appropriate, ie, the number of mcg of parenteral fentanyl per hour should be approximately equal to the number of mcg of transdermal fentanyl per hour. In some patients, additional dose titration of the fentanyl patch may be necessary.
- The fentanyl patch analgesic duration is usually 72 hours but some patients require fentanyl patch replacement every 48 hours.

¹Breitbart W, Chandler S, Egel B, et al. An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. *Oncology* 2000;14:695-702.

²Equianalgesic doses to morphine adapted from Foley K. The treatment of cancer pain. *N Engl J Med* 1985;313:84-95.

³Kornick CA, Santiago-Palma J, Khojainova N, et al. A safe and effective method for converting patients from intravenous to transdermal fentanyl. *Cancer* 2001;92:3056-3061.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued on next page](#)



OPIOID PRINCIPLES, PRESCRIBING, TITRATION, AND MAINTENANCE (5 of 7)

CONVERT OR ROTATE FROM ANOTHER OPIOID TO TRANSDERMAL FENTANYL (continued)

Example of opioid using Table 2 directly:

Case example of converting oral oxycodone to transdermal fentanyl patch

A patient is taking 30 mg of sustained release oral oxycodone every 12-h and needs to be converted to transdermal fentanyl patch.

- 1. Calculate the total amount of current oral oxycodone in a 24-h period.**
(oral oxycodone 30 mg x 2 = 60 mg/day oral oxycodone)
- 2. Using Table 2, select the the mcg per hour dose of transdermal fentanyl**
(60 mg/day oral oxycodone is approximately 50 mcg/h transdermal fentanyl patch)

Example of opioid not listed on Table 2

Case example of converting oral oxymorphone to transdermal fentanyl patch

A patient is taking 10 mg of sustained release oral oxymorphone every 12-h and needs to be converted to transdermal fentanyl patch.

- 1. Calculate the total amount of current oral oxymorphone in a 24-h period**
(oral oxymorphone 10 mg x 2 = 20 mg/day oral oxymorphone)
- 2. From Table 1 on [PAIN-E 2 of 7](#), convert the equianalgesic dose of oral morphine**
(Based on Table 1, 10 mg oral oxymorphone = 30 mg oral morphine, therefore
20 mg/day oral oxymorphone x 3 = total daily dose oral morphine of 60 mg/day)
- 3. Using Table 2 on [PAIN-E 4 of 7](#), select the mcg per hour dose of transdermal fentanyl**
(60 mg/day oral morphine is approximately 25 mcg/h transdermal fentanyl patch)

[Continued on next page](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



OPIOID PRINCIPLES, PRESCRIBING, TITRATION, AND MAINTENANCE (6 of 7)

Special Notes Regarding Oral Methadone:

- Due to the unique nature of methadone with a long and variable half-life, caution should be used and frequent and careful evaluation should be performed.
- The conversion ratio varies with the amount of morphine (or other opioid) a patient has been using chronically. The higher the dose of morphine, the more potent methadone is. PRACTITIONERS ARE ADVISED TO CONSULT WITH A PAIN OR PALLIATIVE CARE SPECIALIST IF THEY ARE UNFAMILIAR WITH METHADONE PRESCRIBING.
- To a significantly greater extent than with other opioids, methadone has been associated with many drug-drug interactions. The potential for such interactions must be investigated in each patient before initiating methadone.
- Methadone is widely available in 5 mg and 10 mg tablets.
- Methadone may be titrated up every 5 - 7 days, usually by 5 mg/dose.
- Methadone is typically given at a regular schedule with additional doses of a short-acting opioid given as needed.
- Because methadone is associated with QTc prolongation, a baseline and follow-up ECG is recommended for methadone doses > 100 mg/day and for patients with cardiac disease, or when methadone is used in patients taking other medications also known to prolong QTc (including tricyclic anti-depressants), if consistent with patient's goals of care. QTc ≥ 450 may indicate need to reduce or discontinue methadone dose.
- These conversion ratios should NOT be used in converting from methadone to other opioids. After methadone is discontinued, it will take several days for it to be cleared, due to a long elimination half-life; therefore, the amount of other opioid needed for an equivalent effect will appear to change as the residual methadone is cleared. On the first day of conversion (while there is still significant methadone present), a conservative conversion ratio for oral methadone to oral morphine of 1:1 may be used, and supplemented with additional short-acting opioid, as needed. As methadone is cleared, morphine (or other opioid) doses will likely require frequent adjustment (every day or two) towards the higher conversion ratios listed for morphine-to-methadone conversion.

[See Convert from Oral Morphine to Oral Methadone \(PAIN-E 7 of 7\)](#)

¹Manfredi PL, Houde RW. Prescribing methadone, a unique analgesic. J Support Oncol 2003;1:216-220.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



OPIOID PRINCIPLES, PRESCRIBING, TITRATION, AND MAINTENANCE (7 of 7)

CONVERT FROM ORAL MORPHINE TO ORAL METHADONE¹

[See Special Notes Regarding Oral Methadone \(PAIN-E 6 of 7\)](#)

- To convert from oral morphine to oral methadone

1. Calculate the total daily oral morphine dose (or morphine-equivalent dose) the patient is using.
2. Based on the oral morphine dose, use Table 3 below to determine the appropriate dose conversion ratio and calculate the oral methadone dose
3. Reduce the calculated equianalgesic dose of oral methadone by 25-50% to account for incomplete cross-tolerance, dosing ratio variability, and patient variability.
4. Divide the total daily oral methadone dose into 3 or 4 daily doses.

Table 3 Dose Conversion Ratios for Oral Morphine to Oral Methadone

<u>ORAL MORPHINE</u>	<u>DOSE CONVERSION RATIO (oral morphine : oral methadone)</u>
30 - 90 mg	4:1
91 - 300 mg	8:1
> 300 mg	12:1

Note: If the total daily dose equivalent of morphine is greater than 800 mg, a higher dose ratio is necessary and dose-titration is recommended. A pain or palliative care specialist should be consulted.

Case example of converting oral morphine to oral methadone

A patient is taking oral morphine at 30 mg every 4-h and needs to be converted to oral methadone

1. Calculate the total amount of current oral morphine in a 24-h period for this patient
(30 mg x 6 = 180 mg/day)
(Total amount of oral morphine this patient is taking is 180 mg/day)
2. From Table 3 above, calculate equianalgesic dose of oral methadone
(For 180 mg/day of oral morphine : oral methadone, the dose conversion ratio is 8:1 therefore
180 mg/day morphine = 22.5 mg/day methadone)
3. Reduce the calculated equianalgesic dose of oral methadone by 25-50% to account for incomplete cross-tolerance, dosing ratio variability, and patient variability
(for example, 22.5 mg/day oral methadone reduced by 25% = 16.875 mg/day oral methadone
equal to approximately 15 mg/day oral methadone)
4. Divide the total daily oral methadone dose into 3 daily doses
(for example, reduced dose of 15 mg/day oral methadone divided by 3 daily doses = 5 mg oral methadone every 8 h)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



MANAGEMENT OF OPIOID ADVERSE EFFECTS (1 of 3)

Principles of Management of Opioid Adverse Effects

- Opioid adverse effects generally improve over time, except with constipation. Maximize non-opioid and nonpharmacologic interventions to limit opioid dose and treat adverse effects. If adverse effects persist, consider opioid rotation.
- Multisystem assessment is necessary.
- Recognize that pain is rarely treated in isolation in cancer and adverse effects may be from other treatments or cancer itself.
- Recognize adverse effects to opioids are common, should be anticipated, and managed aggressively.
- Patient/family education is essential for successful management of pain and opioid adverse effects.
- Information from patient/family about adverse effects is essential for appropriate opioid dose adjustment and treatment of adverse effects.

Constipation

- Preventive measures
 - ▶ Prophylactic medications
 - ◇ Polyethylene glycol (1 capful/8 oz water PO two times a day)
 - ◇ Stimulant laxative ± stool softener (eg, senna ± docusate, 2 tablets every morning; maximum 8-12 tablets per day).
 - ◇ Increase dose of laxative when increasing dose of opioids
 - ▶ Maintain adequate fluid intake
 - ▶ Maintain adequate dietary fiber intake. Compounds such as psyllium (eg, Metamucil) are unlikely to control opioid induced constipation and are not recommended.
 - ▶ Exercise, if feasible
- If constipation develops
 - ▶ Assess for cause and severity of constipation
 - ▶ Rule out obstruction
 - ▶ Treat other causes
 - ▶ Titrate stool softener/laxatives as needed with goal of one non-forced bowel movement every 1-2 d
 - ▶ Consider co-analgesic to allow reduction of the opioid dose
- If constipation persists
 - ▶ Reassess for the cause and severity of constipation, rule out bowel obstruction
 - ▶ Check for impaction
 - ▶ Consider adding another agent, such as magnesium hydroxide, 30-60 mL daily; bisacodyl, 2-3 tablets PO daily, or 1 rectal suppository daily; lactulose, 30-60 mL daily; sorbitol, 30 mL every 2 h x 3, then as needed, or magnesium citrate, 8 oz PO daily, polyethylene glycol (1 capful/8 oz water PO two times a day)
 - ▶ Fleet, saline, or tap water enema
 - ▶ Consider use of a prokinetic agent (eg, metoclopramide, 10-20 mg PO four times a day)
 - ▶ When response to laxative therapy has not been sufficient for opioid-induced constipation in patients with advanced illness, consider methylnaltrexone, 0.15 mg/kg subcutaneously, maximum one dose per day
 - ▶ Consider neuraxial analgesics or neuroablative techniques to potentially reduce opioid dose

[Continued on next page](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



MANAGEMENT OF OPIOID ADVERSE EFFECTS (2 of 3)

Nausea

- **Preventive measures**

- For patients with a prior history of opioid induced nausea, prophylactic treatment with antiemetic agents (see below) are highly recommended.

- **If nausea develops**

- Assess for other causes of nausea (eg, constipation, central nervous system pathology, chemotherapy, radiation therapy, hypercalcemia)
- Consider prochlorperazine, 10 mg PO every 6 h as needed; or thiethylperazine, 10 mg PO every 6 h as needed; or haloperidol, 0.5-1 mg PO every 6-8 h; or metoclopramide, 10-20 mg PO every 6 h as needed
- If nausea persists despite as needed regimen, administer antiemetics around the clock for 1 wk, then change to as needed
- Consider adding a serotonin antagonist (eg, granisetron, 2 mg PO daily; or ondansetron, 8 mg PO three times a day; or dolasetron 100-200 mg PO; or palonosetron 300 mcg/kg IV). Use with caution as constipation is an adverse effect.
- Dexamethasone can be considered

- **If nausea persists for more than 1 wk**

- Reassess cause and severity of nausea
- Consider opioid rotation

- **If nausea persists after a trial of several opioids and above measures**

- Reassess cause and severity of nausea
- Consider neuraxial analgesics or neuroablative techniques to potentially reduce opioid dose

Pruritus

- **If pruritus develops**

- Assess for other causes (other medications, etc.)
- Consider antihistamines such as diphenhydramine, 25-50 mg IV or PO every 6 h; or promethazine, 12.5-25 mg PO every 6 h

- **If pruritus persists**

- Consider changing to another opioid if symptomatic management has failed.
- Consider adding to analgesic regimen: small doses of mixed agonist-antagonist, nalbuphine, 0.5-1 mg IV every 6 h as needed

- **Consider continuous infusion of naloxone, 0.25 mcg/kg/h and titrate up to 1 mcg/kg/h for relief of pruritus without decreasing effectiveness of the analgesic.**

[Continued on next page](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



MANAGEMENT OF OPIOID ADVERSE EFFECTS (3 of 3)

Delirium

- **Assess for other causes of delirium (eg, hypercalcemia, CNS, metastases, other psychoactive medications, etc.)**
- **If one cannot determine other possible causes of delirium, consider changing the opioid**
- **Consider nonopioid analgesic to allow reduction of the opioid dose**
- **Consider haloperidol, 0.5-2 mg PO or IV every 4-6 h; or olanzapine, 2.5-5 mg PO or sublingual every 6-8 h; or risperidone, 0.25-0.5 mg 1-2 times day**
- **For further information about delirium, [see NCCN Palliative Care Guidelines](#)**

Motor and Cognitive Impairment

- **Studies have shown that stable doses of opioids (> 2 wk) are not likely to interfere with psychomotor and cognitive function but these functions should be monitored during analgesic administration and titration.**

Respiratory depression

- **Use reversing agents cautiously. If reversing an opioid with a long half life such as methadone, consider naloxone infusion.**
- **If respiratory problems or acute changes in mental status occur, consider naloxone administration. Dilute one ampule of naloxone (0.4 mg/1 mL) into 9 mL of normal saline for a total volume of 10 mL. Give 1-2 mL (0.04-0.08 mg) every 30-60 seconds until improvement in symptoms is noted. Be prepared to repeat this process (the half-life of opioids is generally longer than that of the naloxone). If the patient is not responsive within 10 minutes and total naloxone dose of 1 mg, consider another reason for the change in neurological status.**

Sedation

- **If sedation develops and persists for more than 1 wk after initiating opioids**
 - ▶ **Assess for other causes of sedation (eg, CNS pathology, other sedating medications, hypercalcemia, dehydration, sepsis, hypoxia)**
 - ▶ **Decrease the dose of opioid if pain control can be maintained at a lower dose**
 - ▶ **Consider changing the opioid**
 - ▶ **Consider nonopioid analgesic to allow reduction of the opioid dose**
 - ▶ **Consider a lower dose of opioid given more frequently to decrease peak concentrations**
 - ▶ **Consider the addition of caffeine, 100-200 mg PO every 6 h; or methylphenidate, 5-10 mg 1-3 times per day; or dextroamphetamine, 5-10 mg PO 1-3 times per day; or modafinil, 100-200 mg per day. When using CNS stimulants for sedation, limit dosing to morning and early afternoon to avoid insomnia at night.**
- **If sedation persists despite several changes of opioids and the above measures**
 - ▶ **Reassess cause and severity of sedation**
 - ▶ **Consider neuraxial analgesics or neuroablative techniques to potentially reduce opioid dose**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



ADJUVANT ANALGESICS FOR NEUROPATHIC PAIN (1 of 2)
(ANTIDEPRESSANTS, ANTICONVULSANTS, AND TOPICAL AGENTS)

Principles of Adjuvant Analgesic Use

- Antidepressant and anticonvulsants are first-line adjuvant analgesics for the treatment of cancer-related neuropathic pain.
- These drugs can be helpful for patients whose pain is only partially responsive to opioids.
- The use of adjuvant analgesics in the cancer population is still often guided solely by anecdotal experience or guidelines derived from data in non-malignant pain populations.
- Effective use is predicated on an assessment that clarifies the nature of the pain.
- As with opioids, it is likely that response to different adjuvant analgesics may vary among types of neuropathic pain and individual patients.
- Drug selection may be influenced by the presence of certain non-pain symptoms and co-morbidities. For example, a sedating drug may be useful in a patient in whom insomnia is a problem.
- Patient education should emphasize the trial and error nature of the treatment so patients do not get discouraged.
- Doses should be increased until the analgesic effect is achieved, adverse effects become unmanageable, or the conventional maximal dose is reached.

[See Examples of Adjuvant Analgesics
Use for Neuropathic Pain \(PAIN-G 2 of 2\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**ADJUVANT ANALGESICS FOR NEUROPATHIC PAIN (2 of 2)**
(ANTIDEPRESSANTS, ANTICONVULSANTS, AND TOPICAL AGENTS)**Examples of Adjuvant Analgesics Use (Extrapolated from non cancer neuropathic pain management)**

- **Trial of antidepressant:** Analgesic effectiveness is not dependent on its antidepressant activity. Effective analgesic dose is often lower than that required to treat depression. The onset of analgesic action is usually earlier. Frequently used as an adjuvant analgesic in combination with an opioid for the neuropathic component of the pain.
 - ▶ Tricyclic antidepressants (eg, amitriptyline, imipramine, nortriptyline, desipramine)
 - ◊ Start with low dose and increase every 3- 5 days if tolerated. (eg, nortriptyline and desipramine starting dose 10- 25 mg nightly increase to 50- 150 mg nightly. The tertiary amines (amitriptyline, imipramine) may be more efficacious but secondary amines (nortriptyline, desipramine) are better tolerated. Anticholinergic adverse effects such as sedation, dryness of mouth, urinary hesitancy are more likely to occur with amitriptyline and imipramine.)
 - ▶ Other examples:
 - ◊ Duloxetine- Starting dose 30- 60 mg daily, increase to 60- 120 mg daily
 - ◊ Venlafaxine- Starting dose 50- 75 mg daily, increase to 75- 225 mg daily
 - ◊ Bupropion- Starting dose 100- 150 mg daily, increase to 150- 450 mg daily
- Note: Some antidepressants, (especially duloxetine, bupropion) may enhance metabolism of tamoxifen and thereby limit tamoxifen efficacy - see discussion ([MS-10](#)).
- **Trial of anticonvulsants:** Frequently used as a adjuvant analgesic in combination with an opioid for the neuropathic component of the pain.
 - ▶ Anticonvulsant examples:
 - ◊ Gabapentin- Starting dose 100- 300 mg nightly, increase to 900- 3,600 mg daily in divided doses two times to three times a day. Dose increments of 50-100% every 3 days. Slower titration for the elderly or medically frail. Dose adjustment required for those with renal insufficiency.
 - ◊ Pregabalin- Starting dose 50 mg three times a day, increase to 100 mg three times a day. Slower titration for the elderly or medically frail. Dose adjustment required for those with renal insufficiency. Pregabalin more efficiently absorbed through the GI tract than gabapentin. May increase further to a maximum dose of 600 mg in divided doses two to three times a day.
 - ◊ Consider other anticonvulsant agents, many of which have been shown to have efficacy in non cancer neuropathic pain.
- **Trial of topical agents:** Act locally and may be used as a adjuvant analgesic in combination with an opioid, antidepressant, and/or an anticonvulsant.
 - ▶ Topical Agent Examples:
 - ◊ Lidocaine patch- 5% - Apply daily to the painful site. Minimal systemic absorption.
 - ◊ Consider NSAID- diclofenac gel 1%, four times daily; or diclofenac patch 180 mg, one patch daily or one patch twice daily
- **Trial of corticosteroids:** Long half-life of these drugs allows for once daily dosing. Useful in the acute management of a pain crisis when neural structures or bones are involved. Long-term adverse effects significant.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PSYCHOSOCIAL SUPPORT

Support

- Inform patient and family that emotional reactions to pain are normal and are evaluated and treated as part of pain treatment.
- Provide emotional support to patients and families that acknowledges the pain is a problem to be addressed.
- Assist in accessing treatment as needed.
- State that you will work together with the patient and family as part of the team to address the pain problem.
- Describe the plan of action to be taken and when results can be expected.
- Express your commitment to staying available until the pain is better managed.
- Verbally repeat your concern and the plan of action to be taken.
- Inform patient and family that there is ALWAYS something else that can be done to try to adequately manage pain and other noxious symptoms.
- Assess impact upon family and significant others and provide education and support as indicated.

Skills training

- Teach coping skills (to be used in conjunction with and not in lieu of appropriate analgesia) to provide pain relief, enhance a sense of personal control, and refocus energy on optimizing quality of life.
 - ▶ Coping skills for acute pain include Lamaze-type breathing exercises, distraction techniques, and cognitive coping statements to encourage assertiveness and to maximize comfort.
 - ▶ Coping skills for chronic pain (not pain emergency) include all of the above plus relaxation techniques, guided imagery, graded task assignments, and hypnosis to maximize function.
- Educate patient and family that pain management is a team effort. Members of the team may include: oncologist, nurse, pain specialist, palliative care clinician, physiatry, neurologist, psychologist, social worker, psychiatrist, physical therapist, and spiritual counselor.

[See Patient and Family Education \(PAIN-I\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PATIENT AND FAMILY EDUCATION (1 of 2)

- **Healthcare team should:**
 - **Assess patient and family for literacy to ensure understanding of education.**
 - **Assess patient and family's existing knowledge of pain and pain treatment to aid in developing appropriate patient/family education plan.^{1,2}**

- **Messages to be conveyed to patient and family**
 - **Morphine and morphine-like medications are principle medication used to relieve severe pain.**
 - **When these drugs are used to treat cancer pain, addiction is rarely a problem.**
 - ◊ **For patients with a history of substance abuse, [see PAIN-L](#).**
 - **If you take these medications now, they will still work later.**
 - **These are controlled substances that need to be properly safeguarded in the home.**
 - **These medications must be used with caution, and should not be mixed with alcohol or illicit substances.**
 - **Relief of pain is medically important and there is no medical benefit to suffering with pain.**
 - **Pain can usually be well-controlled with pain medications. For persistent pain, taking analgesic on a regular schedule will improve pain control.**
 - **If these medications do not work, many other options are available.**
 - **Potent analgesics should be taken only as prescribed and by the person for whom the medication is prescribed; do not self adjust dosage or frequency unless discussed with healthcare provider.**
 - **Patients with pain often have other symptoms (eg, constipation, nausea, fatigue, insomnia, depression) that need to be controlled, management of these other symptoms may facilitate control of pain.**
 - **Communication with the healthcare provider is critical for them to assist in meeting goals of care.**
 - ◊ **Healthcare providers cannot tell how much pain you have unless you tell them. Describing your pain is not viewed as “complaining” but as an essential source of information for your health care provider to adjust your treatment.**
 - ◊ **Healthcare providers want to know about any problems that you think the pain medications may be causing, as there are probably ways to make these better.**
 - ◊ **Tell your healthcare providers if you are having any difficulty getting your medication or concerns about taking them. They have dealt with such issues before and will help you.**
 - ◊ **Expect optimal management for pain and adverse effects. Inform patient of right to expect pain management as part of overall care.**
 - **Information pertaining to local regulations regarding the operation of machinery or motor vehicles while taking potentially sedating medication and advise patient and family accordingly and provide appropriate medical counseling.**

[Continued on next page](#)

¹ Stewart M, Brown JB, Donner A, McWhinney I, et al. The impact of patient centered care on outcomes. The Journal of Family Practice 2000;49:797-804.

² Syrjala KL, Abrams JR, Polissar NL, et al. Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain 2008;135:175-186.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PATIENT AND FAMILY EDUCATION (2 of 2)

- **The following must be reviewed with each patient and family and provided in written form, which is dated:**
 - **A list of each medication prescribed, a description of what each medication is for, and instructions as to how and when to take each one**
 - **A list of potential adverse effects of these medications and what to do if they occur**
 - **A list of all medications to be discontinued**
 - **A list of telephone numbers to reach an appropriate healthcare provider and specific instructions to call regarding:**
 - ◊ **Any problems in getting the prescriptions or taking the medication**
 - ◊ **New pain, change in pain, or pain not relieved with medication**
 - ◊ **Nausea and vomiting that prevents eating for 1 day**
 - ◊ **Problems with bowel movements, including no bowel movements for 3 days**
 - ◊ **Difficulty arousing the patient from sleep easily during the daytime**
 - ◊ **Confusion**
 - **A plan for follow-up visits and/or phone calls.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NONPHARMACOLOGIC INTERVENTIONS

Consider nonpharmacologic interventions in conjunction with pharmacologic interventions as needed. Pain likely to be relieved or function improved with physical, cognitive or interventional modalities:

- **Physical modalities**
 - ▶ Bed, bath, and walking supports
 - ▶ Positioning instruction
 - ▶ Physical therapy
 - ▶ Energy conservation, pacing of activities
 - ▶ Massage
 - ▶ Heat and/or ice
 - ▶ Transcutaneous electrical nerve stimulation (TENS)
 - ▶ Acupuncture or acupressure
 - ▶ Ultrasonic stimulation
- **Cognitive modalities**
 - ▶ Imagery/hypnosis
 - ▶ Distraction training
 - ▶ Relaxation training
 - ▶ Active coping training
 - ▶ Graded task assignments, setting goals, pacing and prioritizing
 - ▶ Cognitive behavioral training
 - ▶ Depression/Distress consultation [See NCCN Distress Management Guidelines](#)
 - ▶ Consider pain and palliative care specialty consultation [See NCCN Palliative Care Guidelines](#)
 - ◊ Complex management
 - ◊ Diagnosis and treatment of underlying condition
 - ▶ Spiritual care
- [See **Interventional Strategies \(PAIN-M\)**](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**NON-OPIOID ANALGESIC (NONSTEROIDAL ANTI-INFLAMMATORY DRUGS [NSAID] AND ACETAMINOPHEN) PRESCRIBING (1 of 2)****NSAID**

- Use NSAIDs with caution in patients at high risk for renal, GI, cardiac toxicities, thrombocytopenia, or bleeding disorder. Note that the potential adverse effects of chemotherapy, such as hematologic, renal, hepatic, and cardiovascular toxicities, can be increased by the concomitant prescription of NSAIDs. Opioid analgesics are a safe and effective alternative analgesic to NSAIDs.
- Use any NSAID that the patient has found effective and tolerated well in the past, otherwise consider ibuprofen to the maximal dose.
 - ▶ Ibuprofen, 400 mg four times a day (daily maximum = 3,200 mg)
 - ▶ If needed, consider short term use of ketorolac, 15- 30 mg IV every 6 h for maximum of 5 days
 - ▶ Compounds that do not inhibit platelet aggregation:
 - ◊ Nonacetylated salicylate
 - ◊ Choline + magnesium salicylate combinations, 1.5- 4.5 g/d in three divided doses
 - ◊ Salsalate, 2-3 g/d in two or three divided doses
 - ◊ Selective COX-2 inhibitor
- NSAID and toxicities
 - ▶ Patients at high risk for *renal toxicities*: age > 60 y, compromised fluid status, multiple myeloma, diabetes, interstitial nephritis, papillary necrosis, and concomitant administration of other nephrotoxic drugs (including cyclosporin, cisplatin) and renally excreted chemotherapy
 - ◊ Treatment of *renal toxicities*: discontinue NSAID if BUN or creatinine doubles or if hypertension develops or worsens
 - ▶ Patients at high risk for *GI toxicities*: age > 60 y, history of peptic ulcer disease or significant alcohol use (3 or more alcoholic beverages/day), major organ dysfunction including hepatic dysfunction, high-dose NSAIDs given for long periods
 - ◊ Treatment of *GI toxicities*: if patient develops gastric upset or nausea, consider discontinuing NSAID or changing to selective COX-2 inhibitor. COX-2 inhibitors are associated with lower incidence of GI adverse effects and do not inhibit platelet aggregation, however, they have not been demonstrated to have reduced renal adverse effects.
 - ◊ Consider adding antacids, H2 receptor antagonists, misoprostol, omeprazole. If patient develops gastrointestinal peptic ulcer or gastrointestinal hemorrhage, discontinue NSAID.
 - ◊ Discontinue NSAID if liver function studies increase 1.5 times the upper limit of normal.
 - ▶ Patients at high risk for *cardiac toxicities*: history of cardiovascular disease or at risk for cardiovascular disease or complications. NSAIDs taken with prescribed anticoagulants, such as warfarin or heparin, may significantly increase the risk of bleeding complications.
 - ◊ Treatment of *cardiac toxicities*: discontinue NSAID if congestive heart failure or hypertension develops or worsens
 - ▶ Monitoring for NSAID toxicities:
 - ◊ Baseline blood pressure, BUN, creatinine, liver function studies [alkaline phosphatase, LDH, SGOT, SGPT], CBC, and fecal occult blood
 - ◊ Repeat every 3 mo to ensure lack of toxicity

[Continued on next page](#)

¹ Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians. A scientific statement from the American Heart Association. *Circulation* 2007;115(12):1634-1642.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NON-OPIOID ANALGESIC (NONSTEROIDAL ANTI-INFLAMMATORY DRUGS [NSAID] AND ACETAMINOPHEN) PRESCRIBING (2 of 2)

• **Further NSAID considerations:**

- ▶ **If two NSAIDs are tried in succession without efficacy, use another approach to analgesia**
- ▶ **If NSAIDs are effective but treatment is limited by toxicities that are not deemed serious, consider trial of another NSAID**
- ▶ **When systemic administration is not feasible, consider topical NSAID preparations.**
- ▶ **Toxicity of anti-cancer treatment may increase the risk profile of anti-inflammatory treatment**

Acetaminophen

- **Acetaminophen, 650 mg every 4 h or 1 g every 6 h (daily maximum 4 g/d). The FDA is currently evaluating daily maximum dosing. Due to concerns with liver toxicity, acetaminophen should be used with caution or not used at all with combination opioid- acetaminophen products to prevent excess acetaminophen dosing.**
- **See FDA website (www.fda.gov) for latest information on acetaminophen adverse effects and dosing.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



SPECIALITY CONSULTATIONS FOR IMPROVED PAIN MANAGEMENT

- **Major indication for referral is:**
 - ▶ Pain likely to be relieved or function improved through consultation delivered by a specialty service provider as suggested below.
Note the specific provider of these services may vary in different treatment settings.
- **Pain and palliative care specialty consultation**
[See NCCN Palliative Care Guidelines](#)
 - ▶ Consider interventional strategies ([See PAIN-M](#))
 - ▶ Management of symptoms refractory to initial treatment
 - ▶ Diagnosis and treatment of underlying condition
 - ▶ Consider palliative sedation for intractable pain
- **Substance abuse and diversion consultation if questions/concerns about medication misuse or diversion**
 - ▶ Evaluation for substance use disorder
 - ▶ Assist with establishing treatment agreements, limit setting, single provider/ pharmacy as needed
 - ▶ Communicate regarding need to accomplish pain relief, but avoid misuse/diversion
- **Depression/Distress consultation**
[See NCCN Distress Management Guidelines](#)
- **Spiritual care consultation**
 - ▶ Determine importance to patient/family and current availability of support
 - ▶ Management of spiritual, existential concerns
- **Psychology consultation**
 - ▶ Cognitive modalities
 - ◇ Imagery/hypnosis
 - ◇ Distraction training
 - ◇ Relaxation training
 - ◇ Active coping training
 - ◇ Graded task assignments, setting goals, pacing and prioritizing
 - ◇ Cognitive behavioral training
- **Physical/occupational therapy, rehabilitation/mobility specialty consultation**
 - ▶ Physical modalities
 - ◇ Bed, bath, and walking supports
 - ◇ Positioning instruction
 - ◇ Energy conservation, pacing of activities
 - ◇ Massage
 - ◇ Heat and/or ice
 - ◇ TENS
 - ◇ Acupuncture or acupressure
 - ◇ Ultrasonic stimulation
 - ▶ Lymphedema management

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



INTERVENTIONAL STRATEGIES

Interventional consultation

• **Major indications for referral:**

- ▶ Pain likely to be relieved with nerve block (eg, pancreas/ upper abdomen with celiac plexus block, lower abdomen with superior hypogastric plexus block, intercostal nerve, or peripheral nerve)
- ▶ Failure to achieve adequate analgesia without intolerable adverse effects (may be handled with intraspinal agents, blocks, spinal cord stimulation, or destructive neurosurgical procedures)

• **Commonly used interventional procedures:**

- ▶ **Regional infusions (requires infusion pump)**
 - ◊ Epidural: easy to place, requires large volumes and an externalized catheter; for infusions of opioids, local anesthetics, clonidine, useful for acute post-operative pain
 - ◊ Intrathecal: easy to internalize to implanted pump; for infusions of opioids, local anesthetics, clonidine, and ziconotide
 - ◊ Regional plexus: for infusions of local anesthetics, to anesthetize single extremity
- ▶ Percutaneous vertebroplasty/kyphoplasty
- ▶ Neurodestructive procedures for well-localized pain syndromes (spinal analgesics are used more frequently)
 - ◊ Head and neck: peripheral nerve block
 - ◊ Upper extremity: brachial plexus neurolysis
 - ◊ Thoracic wall: epidural neurolysis, intercostal neurolysis
 - ◊ Upper abdominal pain (visceral): celiac plexus block, thoracic splanchnicectomy
 - ◊ Midline pelvic pain: superior hypogastric plexus block
 - ◊ Rectal pain: intrathecal neurolysis, midline myelotomy or superior hypogastric plexus block
 - ◊ Unilateral pain syndromes: cordotomy
 - ◊ Consider intrathecal L/S phenol block
- ▶ Neurostimulation procedures for cancer-related symptoms (ie, peripheral neuropathy)
- ▶ Radiofrequency ablation for bone lesions

- **If interventional approaches are appropriate,**
 - ▶ Evaluate which pain site can be relieved
 - ▶ Verify interventional technique will provide sufficient benefit

- **If interventional approaches are not appropriate¹**
 - ▶ Reassess therapeutic plan

¹Infection, coagulopathy, very short or lengthy life expectancy, distorted anatomy, patient unwillingness, medications that increase risk for bleeding (eg, anti-angiogenesis agents such as bevacizumab) or technical expertise is not available.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 05/07/10

NCCN Categories of Evidence and Consensus

Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus.

Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.

Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).

Category 3: The recommendation is based on any level of evidence but reflects major disagreement.

All recommendations are category 2A unless otherwise noted.

Overview

Pain is one of the most common symptoms associated with cancer. Pain is defined as “a sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage.”¹ Cancer pain or cancer-related pain distinguishes pain experienced by cancer patients from that experienced by patients without malignancies. Pain occurs in approximately one quarter of patients with newly diagnosed malignancies, one third of patients undergoing treatment, and three quarters of patients with advanced disease.²⁻⁴ In addition, this is one of the symptoms patients fear most. Unrelieved pain denies them comfort and greatly affects their activities, motivation, interactions with family and friends, and overall quality of life.

The importance of relieving pain and the availability of effective therapies make it imperative that physicians and nurses caring for these patients be adept at the assessment and treatment of cancer pain.⁵⁻⁷ This requires familiarity with the pathogenesis of cancer pain; pain assessment techniques; common barriers to the delivery of appropriate analgesia; and pertinent pharmacologic, anesthetic, neurosurgical, and behavioral approaches to the treatment of cancer pain.

The most widely accepted algorithm for the treatment of cancer pain was developed by the World Health Organization (WHO).^{8,9} It suggests that patients with pain be started on acetaminophen or a nonsteroidal anti-inflammatory drug (NSAID). If this is not sufficient, the patient should be escalated to a “weak opioid,” such as codeine, and subsequently to a “strong opioid,” such as morphine. Although this algorithm has served as an excellent teaching tool, the management of cancer pain is considerably more complex than this three-tiered “cancer pain ladder” suggests.

This clinical practice guideline, developed by the National Comprehensive Cancer Network (NCCN) Adult Cancer Pain panel, is unique in several important ways. First, it contains several required components:

- Pain intensity must be quantified by the patient (whenever possible), as the algorithm bases therapeutic decisions on a numerical value assigned to the severity of the pain;
- A formal comprehensive pain assessment must be performed;
- Reassessment of pain intensity must be performed at specified intervals to ensure that the therapy selected is having the desired effect;
- Psychosocial support must be available; and

- Specific educational material must be provided to the patient.

Second, the guidelines acknowledge the range of complex decisions faced in caring for these patients. As a result, they provide dosing guidelines for nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and co-analgesics. They also provide specific suggestions for titrating and rotating opioids, escalation of opioid dosage, management of opioid adverse effects, and when and how to proceed to other techniques/interventions for the management of cancer pain.

Pathophysiologic Classification

Different types of pain occur in cancer patients. A number of attempts have been made to classify pain according to different criteria. Pain classification includes differentiating between pain associated with tumor, pain associated with treatment, and pain unrelated to either. Acute and chronic pain should also be distinguished from each other when deciding what therapy to use. Therapeutic strategy depends on the pain pathophysiology, which is determined by patient examination and evaluation. There are two predominant mechanisms of pain pathophysiology: nociceptive and neuropathic.^{10, 11}

Nociceptive pain is the result of injury to somatic and visceral structures and the resulting activation of nociceptors. Nociceptors are present in skin, viscera, muscles, and connective tissues. Nociceptive pain can further be divided into somatic pain and visceral pain.¹² Pain described as sharp, well localized, throbbing, and pressure-like is likely to be somatic nociceptive pain. It occurs often after surgical procedures or from bone metastasis. Visceral nociceptive pain is often described as more diffuse, aching, and cramping. It is secondary to compression, infiltration, or distension of abdominal thoracic viscera.

Neuropathic pain results from injury to the peripheral or central nervous system. This type of pain might be described as burning, sharp, or shooting. Examples of neuropathic pain include pain due to spinal stenosis or diabetic neuropathy, or as an adverse effect of chemotherapy (eg, vincristine) or radiation therapy.

Comprehensive Pain Assessment

A comprehensive evaluation is essential to ensure proper pain management. Failure to adequately assess pain frequently leads to poor pain control. This algorithm begins with the premise that all patients with cancer should be screened for pain during the initial evaluation, at regular follow-up intervals, and whenever new therapy is initiated.

If pain is present on a screening evaluation, the pain intensity must be quantified, by the patient (whenever possible). Since pain is inherently subjective, patient's self-report to pain is the current standard of care for assessment. Intensity of pain should be quantified using a 0-10 numerical rating scale, a categorical scale, or a pictorial scale (e.g., The Faces Pain Rating Scale).¹³⁻¹⁵ The Faces Pain Rating Scale may be successful with patients who have difficulty with other scales, for example, children, the elderly, and patients with language or cultural differences or other communication barriers. If the patient is unable to verbally report pain, an alternative method to obtain pain rating and pain assessment must be utilized.

In addition to pain intensity, the patient should be asked to describe the characteristics of their pain (i.e., aching, burning etc.). If the patient has no pain, re-screening should be performed at each subsequent visit or as requested. Identifying the presence of pain through repeated screening is essential to allow implementation of effective pain management.

If the Pain Rating Scale score is above 0, a comprehensive pain assessment is initiated. The comprehensive pain assessment should focus on the type and quality of pain, pain history (such as onset, duration, course, etc.), pain intensity (i.e., pain experienced at rest; with movement; interference with activities); location, referral pattern, radiation of pain; the associated factors that exacerbate or relieve the pain, current pain management plan; patient's response to current therapy; prior pain therapies; important psychosocial factors (such as patient distress, family and other support, psychiatric history, risk factors for aberrant use of pain medication, risk factors for undertreatment of pain, etc); other special issues relating to pain (such as meaning of pain for patient and family, cultural beliefs toward pain and pain expression, spiritual or religious considerations and existential suffering).^{16, 17} Finally, the patient's goals and expectations of pain management should be discussed, including level of comfort and function.

In addition, a thorough physical examination and review of appropriate laboratory and imaging studies are essential for a comprehensive pain assessment. This evaluation should enable caregivers to determine if the pain is related to an underlying cause that requires specific therapy. For example, it is inappropriate to provide only opioids to a patient suffering pain from impending spinal cord compression. Without glucocorticoids and local radiation therapy, the pain is unlikely to be well controlled, and the patient will remain at high risk for spinal cord injury.

The endpoint of comprehensive pain assessment is to diagnose the etiology and pathophysiology (somatic, visceral, or neuropathic) of the pain. Treatment must be individualized based on clinical circumstances and patient wishes, with the goal of maximizing function and quality of life.

Management of Pain

For management of cancer related pain in adults, the algorithm distinguishes three levels of pain intensity, based on a 0-10 numerical rating scale (with 10 being the worst pain): severe pain (7-10); moderate pain (4-6); and mild pain (1-3).^{12, 14}

It is important to separate pain related to an oncologic emergency from pain not related to an oncologic emergency (such as pain due bone fracture or impending fracture of weight bearing bone; brain, epidural, or leptomeningeal metastases; pain related to infection; obstructed or perforated viscus). Pain associated with oncologic emergency should be directly treated while proceeding with treatment of the underlying condition.

In addition, the algorithm distinguishes pain not related to oncologic emergencies in patients not chronically taking opioids from patients (opioid naïve) who have previously or are chronically taking opioids for cancer pain (opioid tolerant), and also anticipated procedure related pain and anxiety.

According to the U.S Food and Drug Administration, "patients considered opioid tolerant are those who are taking at least: 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer." Therefore, patients who do not meet the above definition of opioid tolerant, and who have not had opioid doses at least as much as those listed above for a week or more, are considered to be opioid naïve.

Management of pain not related to an oncologic emergency in opioid naïve patients

Opioid naïve patients (those who are not chronically receiving opioids on a daily basis) experiencing severe pain (i.e. pain intensity rating 7-10) should receive rapid titration of short-acting opioids (see page PAIN-2 and the section below on Opioid Principles, Prescribing, Titration, and Maintenance). Short-acting formulations have the advantage of rapid onset of analgesic effect. The route of administration of opioid is decided (oral versus intravenous) based on what is best suited to the patient's ongoing analgesic needs.

Treatment with opioids must be accompanied with a bowel regimen, and non-opioid analgesics as indicated. Details of prophylactic bowel regimens and antiemetics are provided on page PAIN-F; management of these common opioid adverse effects should be started simultaneously with initiation of opioid therapy. Opioid-induced bowel dysfunction should be anticipated and treated prophylactically with a stimulating laxative to increase bowel motility, with or without stool softeners as indicated.¹⁸

For opioid naïve patients, whose pain intensity rating is between 4-6 at presentation, the pathways are quite similar to those for pain intensity 7-10 (above). The main differences include treatment beginning with slower titration of short-acting opioids.

Opioid naïve patients experiencing mild pain intensity (1-3) should receive treatment with NSAID or acetaminophen or treatment with consideration of slower titration of short-acting opioids.

Addition of co-analgesic for specific pain syndromes should be considered for all groups of patients (see section below on Additional

Therapies and PAIN- G). Co-analgesics are drugs used to enhance the effects of opioids or NSAIDs.¹⁹

For all patients experiencing pain, care providers should also provide psychosocial support and begin educational activities. Psychosocial support is needed to ensure that patients encountering common barriers to appropriate pain control (e.g., fear of addiction or side effects, inability to purchase opioids) or needing assistance in managing additional problems (e.g., depression, rapidly declining functional status) receive appropriate aid. The patient and the family must be educated regarding pain management and related issues.

Although pharmacologic analgesics are the cornerstone of cancer pain management, they are not always adequate and are associated with many side-effects thus often necessitating the implementation of additional therapies or treatments. Optimal use of nonpharmacological interventions may serve as valuable additions to pharmacologic interventions. A list of nonpharmacologic interventions that include physical and cognitive modalities are outlined in PAIN-J and interventional strategies are discussed in the section below and in PAIN-M.

Opioid Principles, Prescribing, Titration, and Maintenance

Selecting an Appropriate Opioid

While starting therapy, attempts should be made to determine the underlying pain mechanism and diagnose the pain syndrome. Optimal analgesic selection will depend on the patient's pain intensity, any current analgesic therapy, and concomitant medical illness(es). Morphine, hydromorphone, fentanyl, oxycodone are the opioids commonly used in the United States. An individual approach should be used to determine opioid starting dose, frequency, and titration in order

to achieve a balance between pain relief and medication adverse effects.

In a patient who has not been exposed to opioids in the past, morphine is generally considered the standard starting drug of choice.^{20, 21} An initial oral dose of 5-15 mg of morphine sulfate or equivalent or 2-5 mg of intravenous morphine sulfate or equivalent is recommended for opioid naïve patients.

Pure agonists (such as codeine, oxycodone, oxymorphone and fentanyl) are the most commonly used medications in the management of cancer pain. The short half-life opioid agonists (morphine, hydromorphone, fentanyl, and oxycodone) are preferred, because they can be more easily titrated than the long half-life analgesics (methadone and levorphanol).²² Transdermal fentanyl is not indicated for rapid opioid titration and only should be recommended after pain is controlled by other opioids.²³ Conversion from intravenous fentanyl to transdermal fentanyl can be accomplished effectively using a 1:1 conversion ratio.²⁴

Morphine should be avoided in patients with renal disease and hepatic insufficiency. Morphine-6-glucuronide, an active metabolite of morphine, contributes to analgesia and may worsen adverse effects as it accumulates in patients with renal insufficiency.^{25, 26}

Individual variations in methadone pharmacokinetics (long half-life ranging from 8 to more than 120 hours) make its usage very difficult in cancer patients.²⁷ Because of its long half-life, high potency, and inter-individual variations in pharmacokinetics, methadone should be started at lower-than-anticipated doses and slowly titrated upwards with provision of adequate short-acting breakthrough pain medications

during the titration period. Consultation with a pain management specialist should be considered before its application.

The following agents namely 1) mixed agonist-antagonists (e.g. butorphanol, pentazocine), 2) propoxyphene and meperidine, and 3) placebos are not recommended for cancer patients. For treatment of severe pain, mixed agonist-antagonist drugs have limited efficacy and may precipitate opioid withdrawal if used in patients receiving pure opioid agonist analgesics. Meperidine and propoxyphene are contraindicated for chronic pain especially in patients with impaired renal function or dehydration, because accumulation of renally-cleared metabolites may result in neurotoxicity or cardiac arrhythmias.²⁸ Use of placebo in the treatment of pain is unethical.

Propoxyphene is an inhibitor of the hepatic enzyme, CYP2D6.^{29, 30} Since data suggests that CYP2D6-inhibiting anti-depressants increase risk of recurrence in breast cancer patients treated with tamoxifen,^{31, 32} (see section on Additional Therapies below) it is reasonable to assume that propoxyphene may have the same effect. Therefore, propoxyphene should be avoided in patients treated with tamoxifen. In general, propoxyphene should be avoided in cancer pain management as its risks far outweigh any benefits.

Selecting a Route of Administration

The least invasive, easiest, and safest route of opioid administration should be provided to ensure adequate analgesia.

Oral is the preferred route of administration for chronic opioid therapy.^{28, 33, 34} The oral route should be considered first in patients who can take oral medications unless a rapid onset of analgesia is required or the patient experiences side-effects associated with the oral administration. Continuous parenteral infusion, intravenous (IV) or subcutaneous (SC),

is recommended for patients who cannot swallow or absorb opioids enterally. Opioids, given parenterally, may produce fast and effective plasma concentrations in comparison with oral or transdermal opioids. Intravenous route is considered for faster analgesia because of the short lag-time between injection and effect (peak 15 minutes) in comparison with oral dosing (peak 60 minutes).³⁵

The following methods of ongoing analgesic administration are widely used in clinical practice: “around the clock”, “as needed”, and “patient-controlled analgesia”. “Around the clock” dosing is provided to chronic pain patients for continuous pain relief. A “rescue dose” should also be provided as a subsequent treatment for patients receiving “around-the-clock” doses. Rescue doses of short-acting opioids should be provided for pain that is not relieved by regularly scheduled, “around-the-clock” doses. Opioids administered on an “as needed” basis are for patients who have intermittent pain with pain-free intervals. The “as needed” method is also used when rapid dose titration is required. The patient-controlled analgesia technique allows a patient to control a device that delivers a bolus of analgesic “on demand” (according to, and limited by, parameters set by a physician).

Opioid Adverse Effects

Constipation, nausea and vomiting, pruritus, delirium, respiratory depression, motor and cognitive impairment, and sedation are fairly common, especially when multiple agents are used.³⁶⁻⁴¹ Each adverse effect requires a careful assessment and treatment strategy. Proper management is necessary to prevent and reduce analgesic adverse effects.^{36, 42-50} Constipation can almost always be anticipated with opioid treatment, administration of prophylactic bowel regimen is recommended. However there is not much evidence on which to base the selection of the most appropriate bowel regimen. There is one study showing that addition of a stool softener, docusate to the laxative,

sennosides was less effective than administering laxative, sennosides alone.⁵¹ Therefore, the NCCN Adult Cancer Pain panel recommends a stimulant laxative with or without a stool softener. The details of prophylactic bowel regimens and other measures to prevent constipation, and antiemetics are provided on page PAIN-F, 1 of 3.

Opioid Rotation

No single opioid is optimal for all patients.⁵² If opioid adverse effects are significant, an improved balance between analgesia and adverse effects might be achieved by changing to an equivalent dose of an alternative opioid. This approach is known as opioid rotation.³⁶ It is important to consider relative effectiveness when switching between oral and parenteral routes to avoid subsequent overdosing or under-dosing. Equianalgesic dose ratios, opioid titration and maintenance and clinical examples of converting from one opioid to another are listed in PAIN-E.

Initiating short-acting opioids in opioid naïve patients

The route of administration of opioid (oral or intravenous) must be selected based on the needs of the patient.

For opioid naïve patients, experiencing pain intensity of greater than or equal to 4 or a pain intensity less than 4 but whose goals of pain control and function are not met, an initial dose of 5-15 mg of oral morphine sulfate or 1-5 mg of intravenous morphine sulfate or equivalent is recommended. Assessment of efficacy and side-effects should be performed every 60 minutes for orally administered opioids and every 15 minutes for intravenous opioids to determine a subsequent dose. Upon assessment, if the pain score remains unchanged or is increased, to achieve adequate analgesia, it is recommended that the dose be increased by 50%-100% of the previous dose of opioid. If the pain score decreases to 4-6, the same dose of opioid is repeated and

reassessment is performed at 60 minutes for orally administered opioids and every 15 minutes for intravenously administered opioids. If inadequate response is seen in patients with moderate to severe pain, upon reassessment after 2-3 cycles of the opioid, changing the route of administration from oral to intravenous or subsequent management strategies can be considered. If the pain score decreases to 0-3, the current effective dose of opioid is administered “as needed” over initial 24 hours before proceeding to subsequent management strategies.

Management of pain that is not related to an oncologic emergency in opioid tolerant patients

Opioid tolerant patients are those chronically taking opioids for pain relief. According to the U.S Food and Drug administration opioid tolerant patients “are those who are taking at least: 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer.”

In opioid tolerant patients, experiencing breakthrough pain of intensity greater than or equal to 4, a pain intensity less than 4 but whose goals of pain control and function are not met, in order to achieve adequate analgesia the previous 24 hour total oral or IV opioid requirement must be calculated and the new “rescue” dose must be increased by 10-20%.^{33,53} Efficacy and side-effects should be assessed every 60 minutes for orally administered opioids and every 15 minutes for intravenous opioids to determine a subsequent dose. Upon assessment, if the pain score remains unchanged or is increased, administration of 50%-100% of the previous rescue dose of opioid is recommended. If the pain score decreases to 4-6, the same dose of opioid is repeated and reassessment is performed at 60 minutes for orally administered opioids and every 15 minutes for intravenously

administered opioids. If pain score remains unchanged upon reassessment after 2-3 cycles of the opioid, in patients with moderate to severe pain, changing the route of administration from oral to intravenous or alternate management strategies can be considered. If the pain score decreases to 0-3, the current effective dose of either oral or intravenous opioid is administered “as needed” over initial 24 hours before proceeding to subsequent management strategies.

Subsequent Management of Pain in Opioid Tolerant Patients

The subsequent treatment is based upon the patient’s continued pain rating score. All approaches for all pain intensity levels must be coupled with psychosocial support and education for patients and their families.

If the pain at this time is severe, unchanged or increased, the working diagnosis must be re-evaluated and comprehensive pain assessment must be carried out. For patients unable to tolerate dose escalation of their current opioid due to adverse effects, an alternate opioid must be considered. Addition of co-analgesics should be re-evaluated to either enhance the analgesic effect of the opioids or in some cases to counter the adverse effects associated with the opioids.¹⁸ Given the multifaceted nature of cancer pain, additional interventions for specific cancer pain syndromes and specialty consultation must be considered to provide adequate analgesia.

If the patient is experiencing moderate pain of intensity 4-6 and if they have adequate analgesic relief on their current opioid, the current titration of the opioid may be continued or increased. In addition, as with patients experiencing severe pain, addition of co-analgesics; additional interventions for specific cancer pain syndromes; and specialty consultation must be considered.

For opioid tolerant patients experiencing mild pain, if they have adequate analgesia but intolerable or unmanageable side-effects the analgesic dose may be reduced by 25% of the current opioid dose. Addition of co-analgesics may be considered.

Ongoing Care

Although pain intensity ratings will be obtained frequently to evaluate opioid dose increases, a formal re-evaluation to evaluate patient's goals of comfort and function is mandated at each contact.

If an acceptable level of comfort and function has been achieved for the patients, and 24 hour opioid requirement is stable, the NCCN Adult Cancer Pain panel recommends converting to an extended-release oral medication (if feasible) or other extended-release formulation (i.e. transdermal fentanyl), or other long-acting agent (e.g. methadone). The subsequent treatment is based upon the patient's continued pain rating score. Rescue doses of the short-acting formulation of the same long-acting drug may be provided during maintenance therapy for the management of pain in cancer patients not relieved by extended-release opioids.

Routine follow-up should be done during each outpatient contact or at least each day for inpatients depending on patient conditions and institutional standards.

Patients should be provided with a written follow-up plan and instructed on the importance of adhering to the medication plan, maintaining clinic appointments, and following-up with clinicians.

If an acceptable level of comfort and function has not been achieved for the patients, universal screening and assessment must be carried out and additional strategies for pain relief considered.

Management of Procedure-Related Pain and Anxiety

Procedure-related pain represents an acute short-lived experience which may be accompanied by a great deal of anxiety. Procedures reported as painful include bone marrow aspirations; wound care; lumbar puncture; skin and bone marrow biopsies; intravenous line, arterial line, central line; and injections. Much of the data available on procedure-related pain come from studies on pediatric patients with cancer which are then extrapolated to adults. Interventions to manage procedure-related pain should take into account the type of procedure, the anticipated level of pain, other individual characteristics of the patients such as age, and physical condition. The interventions may be multi-modal and may include pharmacological and/or nonpharmacological approaches. Local anesthetics can be used to manage procedure-related pain with sufficient time for effectiveness as per package insert. Examples of local anesthetics include lidocaine, prilocaine, and tetracaine. Physical approaches such as cutaneous warming, laser or jet injection, and ultrasound may accelerate the onset of cutaneous anesthesia. Sedatives may also be used. However, deep sedation and general anesthesia must be carried out only by trained professionals. In addition, use of nonpharmacological interventions listed on PAIN-J may be valuable in managing procedure-related pain and anxiety. The major goal of nonpharmacological interventions that include physical and cognitive modalities is to promote a sense of control increasing hope and reducing helplessness that many patients with pain from cancer experience.

Patients usually tolerate procedures better when they know what to expect. Therefore, patients and family members should receive written instructions for managing the pain. Pre-procedure patient education, regarding procedure details and pain management strategies is



essential. Patients and family members should receive written information regarding pain management options.

Interventional Strategies

Some patients experience inadequate pain control despite pharmacological therapy or may not tolerate an opioid titration program because of side effects. Some patients may prefer procedural options instead of a chronic medication regimen. The major indications for referral include patient suffering from pain that is likely to be relieved with nerve block (eg, pancreas/ upper abdomen with celiac plexus block, lower abdomen with superior hypogastric plexus block, intercostal nerve, or peripheral nerve) and/or in patients failing to achieve adequate analgesia without intolerable side effects. For example, a patient with pancreatic cancer who was not tolerating opioids or not receiving adequate analgesia could be offered a celiac plexus block.

Several interventional strategies are available if a patient does not achieve adequate analgesia. Regional infusion of analgesics (epidural, intrathecal, and regional plexus) is one of the approaches. This approach minimizes the distribution of drugs to receptors in the brain, potentially avoiding side-effects of systemic administration. The intrathecal route of opioid administration should be considered in patients with intolerable sedation, confusion, and/or inadequate pain control with systemic opioid administration. This approach is a valuable tool to improve analgesia for patients who have pain from a variety of anatomical locations (e.g., head and neck, upper and lower extremities, trunk).⁵⁴ Neuroablative procedures used for well-localized pain syndromes (e.g., back pain due to facet or sacro-iliac joint arthropathy; visceral pain due to abdominal or pelvic malignancy), percutaneous vertebroplasty/kyphoplasty, neurostimulation procedures (i.e., for

peripheral neuropathy), and radiofrequency ablation for bone lesions have proven successful in pain management especially those failing to achieve adequate analgesia without intolerable effects. These techniques have been demonstrated in some cases, to eliminate or significantly reduce the level of pain, and/or may allow a significant decrease in systemic analgesics.

Interventional strategies listed above are not appropriate if patients are unwilling or in patients with Infections, coagulopathy, or very short life expectancy. Also, the experts performing the interventions must be made aware of any medications that the patient are taking that might increase risk for bleeding (i.e. anticoagulants (warfarin, heparin), antiplatelet agents (clopidogrel, dipyridamole), or anti-angiogenesis agents (bevacizumab). In such case, the patient may have to be of the medication for an appropriate amount of time prior to the pain intervention and may need to continue to stay off the medication for a specified amount of time after the procedure. Interventions are not appropriate if technical expertise is not available.

Additional therapies

Additional strategies specific to the pain situations can be considered. Specific recommendations for inflammatory pain, bone pain, nerve compression or inflammation, neuropathic pain, pain due to bowel obstruction, and pain likely to respond to antineoplastic therapies are provided. Overall, neuropathic pain is less responsive to opioids than pain caused by other pathophysiologies.

Other therapies, including specific non-traditional analgesic drugs, are usually indicated for neuropathic pain syndrome.⁵⁵ For example, a patient with neuropathic pain who failed to gain sufficient relief from opioids would be given a coanalgesic.

Clinically, coanalgesics consist of a diverse range of drug classes, including anticonvulsants⁵⁶ (e.g., gabapentin, pregabalin), antidepressants (e.g., tricyclic antidepressants), corticosteroids, and local anesthetics (e.g., topical lidocaine patch).

Several antidepressants are known inhibitors of hepatic drug metabolism via inhibition of cytochrome P450 enzymes, especially CYP2D6. Tamoxifen is an estrogen receptor blocker commonly used in patients with hormone receptor-positive breast cancer. Tamoxifen undergoes extensive hepatic metabolism, and inhibition of CYP2D6 decreases production of tamoxifen active metabolites, potentially limiting tamoxifen efficacy. Clinical studies indicate increased risk of breast cancer recurrence in tamoxifen-treated breast cancer patients also treated with selective serotonin reuptake inhibitor (SSRI) antidepressants versus those receiving tamoxifen alone.^{31, 32} If concomitant use of SSRI is required in patient receiving tamoxifen, use of a mild CYP2D6 inhibitor (sertraline, citalopram, venlafaxine, escitalopram) may be preferred over a moderate-to-potent inhibitor (paroxetine, fluoxetine, fluvoxamine, bupropion, duloxetine).⁵⁷

Co-analgesics are commonly used to help manage bone pain, neuropathic pain, visceral pain and to reduce systemic opioid requirement and are particularly important in treating neuropathic pain that is resistant to opioids.⁵⁸

Acetaminophen,⁵⁹ NSAIDs including selective COX-2 inhibitors, tricyclic anti-depressants (TCA), anti-convulsant drugs, bisphosphonates, and hormonal therapy are among the most commonly used medications. The NSAID and acetaminophen prescribing guidelines are presented on page PAIN-K. History of peptic ulcer disease, advanced age (>60 years old), male gender, and concurrent corticosteroid therapy should be considered before NSAIDs administration to prevent upper

gastrointestinal tract bleeding and perforation. Well-tolerated proton pump inhibitors are recommended to reduce gastrointestinal side-effects induced by NSAIDs. NSAIDs should be prescribed with caution in patients older than 60 years of age or in those having compromised fluid status, renal insufficiency, concomitant administration of other nephrotoxic drugs, and renally excreted chemotherapy in order to prevent renal toxicities.

Nonpharmacologic specialty consultations for physical modalities (e.g., massage, physical therapy) and cognitive modalities (e.g., hypnosis, relaxation) may provide extremely beneficial adjuncts to pharmacologic interventions.

Attention should also be focused on psychosocial support, providing education to patients and families, and reducing the side effects of the opioid analgesics.

Continued pain ratings should be obtained and documented in the medical record to ensure that the patient's pain remains under good control and goals of treatment are achieved. Specialty consultations can be helpful in providing interventions to assist with difficult cancer pain problems. The major indication for referral to a specialty service provider is if the pain is likely to be relieved or will help patients become functional in their daily activities. These modalities are delivered by a specialty service provider and pain management is accomplished by establishing individualized goals, then providing specific treatment and education for patients. The specialties include physical/occupational therapy, psychosocial supportive services, or interventional modalities.

Summary

In most patients, cancer pain can be successfully controlled with appropriate techniques and safe drugs. The overall approach to pain

management encompassed in these guidelines is comprehensive. It is based on routine pain assessments, utilizes both pharmacologic and nonpharmacologic interventions, and requires ongoing reevaluation of the patient. The NCCN Adult Cancer Pain Practice Guidelines Panel advises that cancer pain can be well controlled in the vast majority of patients if the algorithms presented are systematically applied, carefully monitored, and tailored to the needs of the individual patient.

Recommended readings:

Levy MH, Chwistek M, Mehta RS. Management of chronic pain in cancer survivors. *Cancer J.* 2008;14:401-409.

Levy MH, Samuel TA. Management of cancer pain. *Semin Oncol.* 2005;32:179-193.

Kochhar R, Legrand SB, Walsh D, Davis MP, Lagman R, Rivera NI. Opioids in cancer pain: common dosing errors. *Oncology (Williston Park).* 2003;17:571-575; discussion 575-576, 579.

Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. *Pain.* 1997;70:109-115.

Discussion
update in
progress

References

1. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl 1986; 3:S1 226.
2. Cohen MZ, Easley MK, Ellis C, et al. Cancer pain management and the JCAHO's pain standards: an institutional challenge. J Pain Symptom Manage. 2003;25:519-527.
3. Goudas LC, Bloch R, Gialeli-Goudas M, Lau J, Carr DB. The epidemiology of cancer pain. Cancer Invest. 2005;23:182-190.
4. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9:195-206.
5. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592-596.
6. Martin LA, Hagen NA. Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. J Pain Symptom Manage. 1997;14:99-9117.
7. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1-18.
8. Stjernsward J. WHO cancer pain relief programme. Cancer Surv. 1988;7:195-208.
9. Stjernsward J, Colleau SM, Ventafridda V. The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. J Pain Symptom Manage. 1996;12:65-72.
10. Caraceni A, Weinstein SM. Classification of cancer pain syndromes. Oncology (Williston Park). 2001;15:1627-1640.
11. Hewitt DJ. The management of pain in the oncology patient. Obstet Gynecol Clin North Am. 2001;28:819-846.
12. Portenoy RK. Cancer pain. Epidemiology and syndromes. Cancer. 1989;63:2298-2307.
13. Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain. 2001;93:173-183.
14. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277-284.
15. Soetenga D, Frank J, Pellino TA. Assessment of the validity and reliability of the University of Wisconsin Children's Hospital Pain scale for Preverbal and Nonverbal Children. Pediatr Nurs. 1999;25:670-676.
16. Al-Atiyat HNM. Cultural diversity and cancer pain. Journal of Hospice & Palliative Nursing. 2009;11:154-164.
17. Ezenwa MO, Ameringer S, Ward SE, Serlin RC. Racial and ethnic disparities in pain management in the United States. J Nurs Scholarsh. 2006;38:225-233.
18. American Pain Society. Principles of Analgesic use in the treatment of acute pain and cancer pain. (ed 5th). Glenview, IL: American Pain Society; 2003.
19. Mercadante SL, Berchovich M, Casuccio A, Fulfaro F, Mangione S. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care. 2007;24:13-19.
20. Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol. 2000;55:713-719.



21. Klepstad P, Kaasa S, Skauge M, Borchgrevink PC. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. *Acta Anaesthesiol Scand*. 2000;44:656-664.
22. Cherny NI. The pharmacologic management of cancer pain. *Oncology (Williston Park)*. 2004;18:1499-1515.
23. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. *Br J Cancer*. 2001;84:587-593.
24. Kornick CA, Santiago-Palma J, Khojainova N, Primavera LH, Payne R, Manfredi PL. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. *Cancer*. 2001;92:3056-3061.
25. Tiseo PJ, Thaler HT, Lapin J, Inturrisi CE, Portenoy RK, Foley KM. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. *Pain*. 1995;61:47-54.
26. Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. *Pain*. 1991;47:13-19.
27. Davis MP, Homsy J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. *Support Care Cancer*. 2001;9:442-451.
28. Bruera E, Kim HN. Cancer pain. *JAMA*. 2003;290:2476-2479.
29. Barkin RL, Barkin SJ, Barkin DS. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity. *Am J Ther*. 2006;13:534-542.
30. Goldstein DJ, Turk DC. Dextropropoxyphene: safety and efficacy in older patients. *Drugs Aging*. 2005;22:419-432.
31. Aubert R, Stanek, EJ, Yao J, Teagarden JR, Subar M, Epstein RS, et al. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. *J Clin Oncol* 2009;27:18S, (suppl; abstract CRA508) .
32. Dezentje V, Van Blijderveen NJ, Gelderblom H, Putter H, Van Herk-Sukel M, Casparie MK, et al. Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study. *J Clin Oncol* 2009;27:18S, (suppl; abstract CRA509).
33. Portenoy RK, Lesage P. Management of cancer pain. *Lancet*. 1999;353:1695-1700.
34. Stevens RA, Ghazi SM. Routes of opioid analgesic therapy in the management of cancer pain. *Cancer Control*. 2000;7:132-141.
35. Harris JT, Suresh Kumar K, Rajagopal MR. Intravenous morphine for rapid control of severe cancer pain. *Palliat Med*. 2003;17:248-256.
36. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. *J Pain*. 2003;4:231-256.
37. Mercadante S. Comments on Wang et al., *PAIN*, 67 (1996) 407-416. *Pain*. 1998;74:106-107.
38. Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. *Pain*. 1998;74:5-9.
39. Wilson RK, Weissman DE. Neuroexcitatory effects of opioids: patient assessment #57. *J Palliat Med*. 2004;7:579.
40. Moryl N, Carver, A, Foley KM. ed Pain and palliation. In: Holland JF, Frei E, eds *Cancer Medicine*. Vol. 17th ed. Hamilton, ON: BC Decker Inc; 2006:1113-1124.



41. Moryl N, Obbens EA, Ozigbo OH, Kris MG. Analgesic effect of gefitinib in the treatment of non-small cell lung cancer. *J Support Oncol.* 2006;4:111-111.
42. Boettger S, Breitbart W. Atypical antipsychotics in the management of delirium: a review of the empirical literature. *Palliat Support Care.* 2005;3:227-237.
43. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. *Am J Psychiatry.* 1996;153:231-237.
44. Bruera E, Belzile M, Neumann C, Harsanyi Z, Babul N, Darke A. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. *J Pain Symptom Manage.* 2000;19:427-435.
45. Challoner KR, McCarron MM, Newton EJ. Pentazocine (Talwin) intoxication: report of 57 cases. *J Emerg Med.* 1990;8:67-74.
46. Katcher J, Walsh D. Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride. *J Pain Symptom Manage.* 1999;17:70-72.
47. Marinella MA. Acute colonic pseudo-obstruction complicated by cecal perforation in a patient with Parkinson's disease. *South Med J.* 1997;90:1023-1026.
48. Reissig JE, Rybarczyk AM. Pharmacologic treatment of opioid-induced sedation in chronic pain. *Ann Pharmacother.* 2005;39:727-731.
49. Tarcatu D, Tamasdan C, Moryl N, Obbens E. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. *J Opioid Manag.* 2007;3:167-170.
50. Prommer E. Modafinil: is it ready for prime time? *J Opioid Manag.* 2006;2:130-136.
51. Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. *J Palliat Med.* 2008;11:575-581.
52. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. *Curr Med Res Opin.* 2009;25:2133-2150.
53. Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. *J Pain Symptom Manage.* 2005;30:485-491.
54. Greenberg HS, Taren J, Ensminger WD, Doan K. Benefit from and tolerance to continuous intrathecal infusion of morphine for intractable cancer pain. *J Neurosurg.* 1982;57:360-364.
55. Chen H, Lamer TJ, Rho RH, et al. Contemporary management of neuropathic pain for the primary care physician. *Mayo Clin Proc.* 2004;79:1533-1545.
56. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. *Oncologist.* 2004;9:571-591.
57. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. *J Natl Cancer Inst.* 2005;97:30-39.
58. Manfredi PL, Gonzales GR, Sady R, Chandler S, Payne R. Neuropathic pain in patients with cancer. *J Palliat Care.* 2003;19:115-118.
59. Stockler M, Vardy J, Pillai A, Warr D. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. *J Clin Oncol.* 2004;22:3389-3394.